10/784,916 8/11/05

NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

1 / CAPLUS broaden structure search 19 hits

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * *

2 / BEILSTEIN 8 hits

FILE 'HOME' ENTERED AT 18:38:39 ON 11 AUG 2005

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:38:47 ON 11 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 AUG 2005 HIGHEST RN 859511-21-0
DICTIONARY FILE UPDATES: 10 AUG 2005 HIGHEST RN 859511-21-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10784916\10784916d.str



chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 18 19
chain bonds :
1-2 2-3 2-18 3-4 4-5 5-6 6-7 6-8 8-9 9-10 10-11 10-12 12-13 13-14 14-15 14-16 14-19
exact/norm bonds :
1-2 2-3 2-18 3-4 4-5 5-6 6-7 6-8 8-9 9-10 10-11 10-12 12-13 13-14 14-15 14-16 14-19

G1:C,O,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 18:CLASS 19:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



G1 C,O,N

Structure attributes must be viewed using STN Express query preparation.

=> s L1
SAMPLE SEARCH INITIATED 18:39:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 17 TO ITERATE

100.0% PROCESSED 17 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

```
FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:            93 TO      587
PROJECTED ANSWERS:                0 TO        0

L2            0 SEA SSS SAM L1

=> s L1 full
FULL SEARCH INITIATED 18:39:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    437 TO ITERATE

100.0% PROCESSED      437 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L3            0 SEA SSS FUL L1

=> fil reg
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     162.19     162.40

FILE 'REGISTRY' ENTERED AT 18:40:27 ON 11 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   10 AUG 2005  HIGHEST RN 859511-21-0
DICTIONARY FILE UPDATES:  10 AUG 2005  HIGHEST RN 859511-21-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10784916\10784916e.str
```



chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 18
ring/chain nodes :
19
chain bonds :
1-2 2-3 2-18 3-4 4-5 5-6 6-7 6-8 8-9 9-10 10-11 10-12 12-13 13-14 14-15 14-16 14-19
exact/norm bonds :
1-2 2-3 2-18 3-4 4-5 5-6 6-7 6-8 8-9 9-10 10-11 10-12 12-13 13-14 14-15 14-16 14-19

G1:C,O,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 18:CLASS 19:CLASS

L4 STRUCTURE UPLOADED

=> d
L4 HAS NO ANSWERS
L4 STR



G1 C,O,N

Structure attributes must be viewed using STN Express query preparation.

=> s L4
SAMPLE SEARCH INITIATED 18:40:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 56 TO ITERATE

100.0% PROCESSED 56 ITERATIONS 5 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 672 TO 1568
PROJECTED ANSWERS: 5 TO 234

L5 5 SEA SSS SAM L4

=> s L4 full
FULL SEARCH INITIATED 18:41:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1291 TO ITERATE

100.0% PROCESSED 1291 ITERATIONS 110 ANSWERS
SEARCH TIME: 00.00.01

L6 110 SEA SSS FUL L4

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 161.33 323.73

FILE 'CAPLUS' ENTERED AT 18:41:04 ON 11 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 11 Aug 2005 VOL 143 ISS 7
FILE LAST UPDATED: 10 Aug 2005 (20050810/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L6
L7 19 L6

=> d ibib abs hitstr

L7 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:527407 CAPLUS
DOCUMENT NUMBER: 143:59982
TITLE: Preparation of HIV protease inhibitors, in particular imidazolidine derivatives
INVENTOR(S): Flentge, Charles A.; Chen, Hui-Ju; Degoey, David A.; Flosi, William J.; Grampovnik, David J.; Huang, Peggy P.; Kempf, Dale J.; Klein, Larry L.; Krueger, Allan C.; Madigan, Darold L.; Randolph, John T.; Sun, Minghua; Yeung, Ming C.; Zhao, Chen
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 287 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005131042	A1	20050616	US 2003-733915	20031211
WO 2005061450	A2	20050707	WO 2004-US37745	20041110

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-733915 A 20031211
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. of formula ANH(CHR)(CHR1)(CHR2)NR3S(O2)R4 (I) [wherein A = alkylcarbonyl, arylsulfonyl, 1,3-substituted 2-oxoimidazolidinyl, 2,4-dioxoimidazolidinyl, etc.; X, Y = independently O, S, NH; R = (un)substituted alk(en)yl, cycloalk(en)yl, hetero/arylalkyl, etc.; R1 = OH and derivs., OPO3H and derivs., OSO2H and derivs., etc.; R2 = H; R3 = halo/alkyl, halo/alkenyl, (un)substituted cycloalk(en)yl, aryl; R4 = (un)substituted cycloalk(en)yl, heterocyclyl, hetero/aryl] were prepared as HIV protease inhibitors. For example, II was prepared, in 62% yield, by coupling acid III (preparation given) with amine IV (preparation given). I showed antiviral activity against Wild-Type HIV with EC50 in the range of 1 nM to 100 nM.

IT **854742-03-3P 854742-27-1P 854742-66-8P**
854742-68-0P 854742-79-3P 854742-80-6P
854746-70-6P 854746-71-7P 854746-72-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiviral agent; preparation of HIV protease inhibitors, in particular imidazolidine derivs.)

L7 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 854742-03-3 CAPLUS
CN Carbamic acid, [(1S)-3-amino-1-[[[(1S,2R)-2-hydroxy-3-[[[4-[(E)-(hydroxyimino)methyl]phenyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-3-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 854742-27-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 854742-66-8 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-2-[3-[(2-methyl-4-thiazolyl)methyl]-2-oxo-1-imidazolidinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 854742-68-0 CAPLUS
CN Pentanediamide, N-[(1S,2R)-2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-2-[3-[(2-methyl-4-thiazolyl)methyl]-2-oxo-1-imidazolidinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 854742-79-3 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-N4-methyl-2-[3-[(2-methyl-4-thiazolyl)methyl]-2-oxo-1-imidazolidinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 854742-80-6 CAPLUS
CN Butanediamide, N4-ethyl-N1-[(1S,2R)-2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-2-[3-[(2-methyl-4-thiazolyl)methyl]-2-oxo-1-imidazolidinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 854746-70-6 CAPLUS
CN Pentanediamide, N5-[(1S,2R)-2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-2-[3-[(2-methyl-4-thiazolyl)methyl]-2-oxo-1-imidazolidinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 854746-71-7 CAPLUS
CN Butanediamide, N-[(1S,2R)-2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-N'-[(2S)-2-[3-[(2-methyl-5-thiazolyl)methyl]-2-oxo-1-imidazolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 854746-72-8 CAPLUS
CN Butanediamide, N-[(1S,2R)-2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-N'-[(2S)-2-[3-[(2-methyl-5-thiazolyl)methyl]-2-oxo-1-imidazolidinyl]-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



```
=> d ibib abs hitstr 2-19
```

L7 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:322087 CAPLUS
DOCUMENT NUMBER: 140:399222
TITLE: BREED: Generating Novel Inhibitors through Hybridization of Known Ligands. Application to CDK2, P38, and HIV Protease
AUTHOR(S): Pierce, Albert C.; Rao, Govinda; Bemis, Guy W.
CORPORATE SOURCE: Vertex Pharmaceuticals, Cambridge, MA, 02139, USA
SOURCE: Journal of Medicinal Chemistry (2004), 47(11), 2768-2775
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In this work we describe BREED, a method for the generation of novel inhibitors from structures of known ligands bound to a common target. The method is essentially an automation of the common medicinal chemical practice of joining fragments of two known ligands to generate a new inhibitor. The ligand-bound target structures are overlaid, all overlapping bonds in all pairs of ligands are found, and the fragments on each side of each matching bond are swapped to generate the new mols. Since the method is automated, it can be applied recursively to generate all possible combinations of known ligands. In an application of this method to HIV protease inhibitors and protein kinase inhibitors, hundreds of new mol. structures were generated. These included known inhibitor scaffolds not included in the initial set, entirely novel scaffolds, and novel substituents on known scaffolds. The method is fast, and since all of the ligand functional groups are known to bind the target in the precise position and orientation present in the novel ligand, the success rate of this method should be superior to more traditional de novo design techniques. In an era of increasingly high-throughput structural biol., such methods for high-throughput utilization of structural information will become increasingly valuable.

IT 688359-10-6
RL: BSU (Biological study, unclassified); BIOL (Biological study) (novel method BREED for generating novel inhibitors through bond-matching and fragment swapping of known ligands)
RN 688359-10-6 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:304314 CAPLUS
DOCUMENT NUMBER: 132:322147
TITLE: Preparation of α- and β-amino acid hydroxyethylamino sulfonamides as retro viral protease inhibitors.
INVENTOR(S): Vazquez, Michael L.; Mueller, Richard A.; Talley, John J.; Getman, Daniel P.; Decrescenzo, Gary A.; Freskos, John N.; Heintz, Robert M.; Bertenshaw, Deborah E.
PATENT ASSIGNEE(S): G.D.Searle and Co., USA
SOURCE: U.S., 93 pp., Cont.-in-part of Appl. PCT/US93/07814.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6060476	A	20000509	US 1994-204827	19940302
WO 9404492	A1	19940303	WO 1993-US7814	19930824
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 810209	A2	19971203	EP 1997-113434	19930824
EP 810209	A3	19981202		
EP 810209	B1	20020605		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
WO 9506030	A1	19950302	WO 1994-US9139	19940823
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9476697	A1	19950321	AU 1994-76697	19940823
EP 715618	A1	19960612	EP 1994-927162	19940823
EP 715618	B1	19981216		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 174587	E	19990115	AT 1994-927162	19940823
ES 2127938	T3	19990501	ES 1994-927162	19940823
US 5968942	A	19991019	US 1994-294468	19940823
US 6455581	B1	20020924	US 1995-451090	19950525
US 6248775	B1	20010619	US 1999-288080	19990408
US 6500832	B1	20021231	US 2000-525161	20000314
US 2002052399	A1	20020502	US 2001-798255	20010305
US 6417387	B2	20020709		
US 2003191319	A1	20031009	US 2002-157019	20020530
US 6646010	B2	20031111		
US 2004044047	A1	20040304	US 2002-199481	20020722
US 6846954	B2	20050125		
US 6924286	B1	20050802	US 2003-633376	20030804
US 2004229922	A1	20041118	US 2004-812343	20040330
PRIORITY APPLN. INFO.:			US 1992-934984	B2 19920825
			WO 1993-US7814	A2 19930824
			EP 1993-923714	A3 19930824
			US 1993-110911	A 19930824
			US 1994-204827	A 19940302
			US 1994-294468	A1 19940823

L7 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

	WO 1994-US9139	W 19940823
	US 1995-451090	A3 19950525
	US 1999-288080	A1 19990408
	US 2001-798255	A1 20010305
	US 2002-157019	A1 20020530
	US 2002-199481	A3 20020722

OTHER SOURCE(S): MARPAT 132:322147
GI



I



II

AB Amino acid hydroxyethylamino sulfonamide compds. I [R2 = (un)substituted aryl, (cyclo)alkyl, aralkyl, cycloalkylalkyl; R3 = alkyl, haloalkyl, alkenyl, alkynyl, hydroxy-, alkoxy-, alkylthio-, or alkylsulfonylalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, or heteroaralkyl; R4 = heterocycloalkyl, heteroaryl or aryl; Y = O or S; A = heterocycloalkyl, heterocycloalkoxy, heterocycloalkylalkoxy, heteroaralkyl, heteroarylalkoxy, heteroacyloxy or heteroaryl] were prepared as retroviral protease inhibitors, particular as inhibitors of HIV protease. Thus, compound II (Cbz = benzyloxycarbonyl) was prepared and assayed for HIV inhibitory activity (IC50 = 16 nM). Compds. of formula I were tested for cytotoxicity and efficacy (IC50, EC50 and TD50 values at the nanomolar level are tabulated).

IT 159005-92-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(amino acid hydroxyethylamino sulfonamides as retroviral protease inhibitors)
RN 159005-92-2 CAPLUS
CN Carbamic acid, [(1S)-3-amino-1-[[[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-3-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 159005-89-7P 159005-91-1P 159005-95-5P 159006-21-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid hydroxyethylamino sulfonamides as retroviral protease inhibitors)
RN 159005-89-7 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(methylsulfonyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159005-91-1 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 159005-95-5 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-N4-methyl-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159006-21-0 CAPLUS
CN Carbamic acid, [(1S)-3-amino-1-[[[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylsulfonyl)propylamino]propyl]amino]carbonyl]-3-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **159005-90-0P 159006-05-0P 159006-22-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(amino acid hydroxyethylamino sulfonamides as retroviral protease

L7 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
inhibitors)

RN 159005-90-0 CAPLUS
CN 2-Thia-3,7,10-triazaundecan-11-oic acid, 9-(2-amino-2-oxoethyl)-5-hydroxy-3-(3-methylbutyl)-8-oxo-6-(phenylmethyl)-, phenylmethyl ester, 2,2-dioxide, (5R,6S,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159006-05-0 CAPLUS
CN Butanediamide, 2-amino-N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(methylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159006-22-1 CAPLUS
CN Carbamic acid, [(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-3-(methylamino)-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:220728 CAPLUS
DOCUMENT NUMBER: 132:265504
TITLE: Preparation of hydroxyethylamino sulfonamides useful as retroviral protease inhibitors.
INVENTOR(S): Vazquez, Michael L.; Mueller, Richard A.; Talley, John J.; Getman, Daniel P.; Decrescenzo, Gary A.; Freskos, John N.; Bertebshaw, Deborah E.; Heintz, Robert M.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: U.S., 119 pp., Cont.-in-part of U.S. 204,872, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6046190	A	20000404	US 1996-586866	19960124
WO 9404492	A1	19940303	WO 1993-US7814	19930824
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 810209	A2	19971203	EP 1997-113434	19930824
EP 810209	A3	19981202		
EP 810209	B1	20020605		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
WO 9506030	A1	19950302	WO 1994-US9139	19940823
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:
US 1992-934984 B2 19920825
WO 1993-US7814 A2 19930824
US 1994-204872 B2 19940302
WO 1994-US9139 W 19940823
EP 1993-923714 A3 19930824
US 1993-110911 A 19930824
US 1994-204827 A 19940302

OTHER SOURCE(S): MARPAT 132:265504

AB Hydroxyethylamino sulfonamide compds. R9R10N(CR7R8)pCHR1C(:Y)NR6CHR2CH(OH)CH2NR3S(:O)xR4 [I: R1 = H, CH2SO2NH2, CH2CO2CH3, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, amino acid side chains, etc.; R2 = (un)substituted alkyl, aryl, cycloalkyl, cycloalkylalkyl, aralkyl; R3 = H, alkyl, haloalkyl, alkenyl, alkynyl, aryl, heteroaryl, mono- and disubstituted aminoalkyl, etc.; R4 = alkyl, haloalkyl, alkenyl, alkynyl, aryl, (un)saturated heterocycle, (un)substituted aromatic heterocycloalkyl, etc.; R6 = H, alkyl; Y = O, S, NR3; R7,R8 = independently H, R1, or together with R1 and the carbon atoms to which they are attached represent a cycloalkyl radical; R9 = H, R3, or R3SO2; R10 = H, alkoxycarbonyl, alkylcarbonyl, aroyl, aryloxycarbonyl, heterocyclylalkoxycarbonyl, mono- and disubstituted aminocarbonyl, or aminoalkanoyl, etc.; or R9R10N = heterocycloalkyl or heteroaryl; x = 0-2; p = 0-1] or their pharmaceutically acceptable salts, prodrugs, or esters were prepared as inhibitors of retroviral proteases such as human immunodeficiency virus

(HIV). Many inhibitors were prepd. by (1) prepg. an N-protected amino epoxide and (2) reacting this with an amine and (3) prepg. a sulfonamide by reacting with a sulfonyl chloride or sulfonyl anhydride in the presence of an acid scavenger. The amino function of the sulfonamide was then (4) deprotected and (5) reacted with a carboxylate. Thus, N1-[2R-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamide was prepd. and assayed for HIV protease inhibitory activity (IC50 = 1.5 nM). Compds. of formula I were tested for cytotoxicity and antiviral efficacy (IC50, EC50, and TD50 values at the nanomolar level are tabulated).

IT **159005-89-7P 159005-91-1P 159005-92-2P**
159005-95-5P 159006-21-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxyethylamino sulfonamides useful as retroviral protease inhibitors)

RN 159005-89-7 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(methylsulfonyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159005-91-1 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159005-92-2 CAPLUS
CN Carbamic acid, [(1S)-3-amino-1-[[[(1S,2R)-2-hydroxy-3-[(3-

methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-3-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159005-95-5 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-N4-methyl-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159006-21-0 CAPLUS
CN Carbamic acid, [(1S)-3-amino-1-[[[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylsulfonyl)propylamino]propyl]amino]carbonyl]-3-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **159005-90-0P 159006-05-0P 159006-06-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxyethylamino sulfonamides useful as retroviral protease inhibitors)

RN 159005-90-0 CAPLUS
CN 2-Thia-3,7,10-triazaundecan-11-oic acid, 9-(2-amino-2-oxoethyl)-5-hydroxy-3-(3-methylbutyl)-8-oxo-6-(phenylmethyl)-, phenylmethyl ester, 2,2-dioxide, (5R,6S,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159006-05-0 CAPLUS
CN Butanediamide, 2-amino-N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(methylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159006-06-1 CAPLUS
CN Butanediamide, 2-amino-N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:811207 CAPLUS
DOCUMENT NUMBER: 132:49801
TITLE: Preparation of 1-acylamino-3-(N-arylsulfonyl-N-alkoxyamino)-2-hydroxypropanes and related compounds as inhibitors of HIV aspartyl protease.
INVENTOR(S): Sherrill, Ronald George; Hale, Michael R.; Spaltenstein, Andrew; Furfine, Eric Steven; Andrews, Clarence Webster, III; Lowen, Gregory Thomas
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 344 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9965870	A2	19991223	WO 1999-US13744	19990617
WO 9965870	A3	20010315		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2335477	AA	19991223	CA 1999-2335477	19990617
AU 9945760	A1	20000105	AU 1999-45760	19990617
AU 767728	B2	20031120		
EP 1086076	A1	20010328	EP 1999-928769	19990617
EP 1086076	B1	20041222		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9912169	A	20010410	BR 1999-12169	19990617
NZ 508855	A	20031031	NZ 1999-508855	19990617
AT 285396	E	20050115	AT 1999-928769	19990617
ES 2235492	T3	20050701	ES 1999-928769	19990617
US 2002049201	A1	20020425	US 2000-731129	20001206
US 6613743	B2	20030902		
NO 2000006405	A	20010219	NO 2000-6405	20001215
US 2004097594	A1	20040520	US 2003-600937	20030620
NZ 528074	A	20041126	NZ 2003-528074	20030908

PRIORITY APPLN. INFO.: US 1998-90094P P 19980619
WO 1999-US13744 W 19990617
US 2000-731129 A3 20001206

OTHER SOURCE(S): MARPAT 132:49801

AB ABxN(Gx)CHDCHOR7CH2ND'SO2E [A = H, (substituted) Ht, R1Ht, R1Ak; Ak = alkyl; Ht = cycloalkyl, cycloalkenyl, (substituted) aryl, heterocyclyl; R1 = CO, SO2, COCO, O2C, NR2CO, NR2SO2, etc.; B = null, NR2C(R3)2CO; x = 0, 1; R2 = H, (substituted) Ht, alkyl; R3 = H, (substituted) Ht, alkyl, alkenyl, cycloalkyl, cycloalkenyl; G = null, H, R7, alkyl; G may be bound to R7; D = (substituted) Q, alkyl, alkenyl; Q = (substituted) carbocyclyl, heterocyclyl; D' = OR10, N:R10, N(R10)R13; E = Ht, OHt, OR3, NR2R3, (substituted) alkyl, alkenyl, etc.; R7 = H, (CH2O)xY(ZM)(:X)Z(M)x, etc.; M = null, H, Li, Na, K, Mg, Ca, Ba, alkyl, alkenyl, etc.; X = O, S; Y = P, S; Z = O, S, N(R2)2, H], were prepared as inhibitors of HIV aspartyl protease (no data). Thus, 3-H2NC6H4SO2NHOCHMe2 (preparation given), tert-Bu

N-(1S)-1-[(2S)-oxiran-2-yl]-2-phenylethylcarbamate, and phosphazene base P4 tert-Bu were stirred in 8 h in THF to give 95% tert-Bu N-(1S,2R)-3-[[(3-aminophenyl)sulfonyl](isopropoxy)amino]-1-benzyl-2-hydroxypropylcarbamate.

IT 252871-32-2P 252871-33-3P 252871-34-4P
252871-35-5P 252871-52-6P 252871-57-1P
252871-63-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-acylamino-3-(N-arylsulfonyl-N-alkoxyamino)-2-hydroxypropanes and related compds. as inhibitors of HIV aspartyl protease)

RN 252871-32-2 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[(3-aminophenyl)sulfonyl](cyclopentyloxy)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252871-33-3 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[(cyclopentyloxy)[(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252871-34-4 CAPLUS
CN Carbamic acid, [5-[[[(2R,3S)-3-[[(2S)-4-amino-1,4-dioxo-2-[(2-quinolinylcarbonyl)amino]butyl]amino]-2-hydroxy-4-phenylbutyl](cyclopentyloxy)amino]sulfonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 252871-35-5 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[(cyclopentyloxy)(1H-indazol-6-ylsulfonyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252871-52-6 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[(cyclohexyloxy)[(4-methoxyphenyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252871-57-1 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](1-methylpropoxy)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252871-63-9 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl][(tetrahydro-2H-pyran-4-yl)oxy]amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:722916 CAPLUS
DOCUMENT NUMBER: 131:336822
TITLE: Preparation of succinamide inhibitors of interleukin-1β converting enzyme
INVENTOR(S): Caprathe, Bradley William; Gilmore, John Lodge; Harter, William Glen; Hays, Sheryl Jeanne; Knapp, Kristen Michele; Kostlan, Catherine Rose; Lunney, Elizabeth Ann; Para, Kimberly Suzanne; Galatsis, Paul; Thomas, Anthony Jerome
PATENT ASSIGNEE(S): Warner-Lambert Company, USA; BASF Aktiengesellschaft
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9956765	A1	19991111	WO 1999-US9463	19990430
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2327507	AA	19991111	CA 1999-2327507	19990430
AU 9936730	A1	19991123	AU 1999-36730	19990430
AU 758120	B2	20030313		
EP 1082127	A1	20010314	EP 1999-918930	19990430
EP 1082127	B1	20050622		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200003252	T2	20010420	TR 2000-200003252	19990430
EE 200000644	A	20020415	EE 2000-644	19990430
JP 2002513766	T2	20020514	JP 2000-546789	19990430
AT 298242	E	20050715	AT 1999-918930	19990430
NO 2000005537	A	20001220	NO 2000-5537	20001102
HR 2000000744	A1	20010630	HR 2000-744	20001103
ZA 2000006881	A	20020525	ZA 2000-6881	20001123
BG 105002	A	20010731	BG 2000-105002	20001129
PRIORITY APPLN. INFO.:			US 1998-84320P P	19980505
			WO 1999-US9463 W	19990430

OTHER SOURCE(S): MARPAT 131:336822
GI



I II III IV

AB The title compds. [I; Y = II-IV (wherein R11 = H, alkyl; X = H, (CH2)nN(R11)SO2(CH2)n-aryl, (CH2)nN(R11)SO2(CH2)n-substituted aryl, etc.); R1, R2 = H, alkyl, (CH2)n-substituted aryl, etc.; n = 0-6; R3 = H, alkyl; R4 = alkyl, H] and their salts, useful for treating stroke, inflammatory diseases such as rheumatoid arthritis or inflammatory bowel disease, septic shock, reperfusion injury, Alzheimer's disease, shigellosis, and multiple sclerosis, were prepared E.g., a detailed 6-step synthesis of I [R1 = Ph(CH2)2; R2 = R3 = H; R4 = Me; R11 = H; Y = CH(CH2CO2H)COCH2NHSO2(CH2)2Ph] which showed IC50 of 14.50 μM against ICE, was given.

IT **249539-55-7P 249539-56-8P 249539-58-0P**
249539-59-1P 249539-60-4P 249539-61-5P
249539-64-8P 249539-66-0P 249539-67-1P
249539-73-9P 249539-74-0P 249539-75-1P
249539-76-2P 249539-77-3P 249539-79-5P
249539-85-3P 249539-88-6P 249539-90-0P
249539-91-1P 249539-93-3P 249539-95-5P
249539-97-7P 249539-98-8P 249540-01-0P
249540-03-2P 249540-05-4P 249540-06-5P
249540-09-8P 249540-12-3P 249540-55-4P
249540-56-5P 249540-57-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of succinamide inhibitors of interleukin-1β converting enzyme)

RN 249539-55-7 CAPLUS
CN Pentanoic acid, 3-[[2-methyl-1,4-dioxo-4-[(2-phenylethyl)amino]butyl]amino]-4-oxo-5-[[(2-phenylethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 249539-56-8 CAPLUS

L7 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN Pentanoic acid, 3-[[(2S)-4-amino-2-(1-methylethyl)-1,4-dioxobutyl]amino]-5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249539-58-0 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-1,4-dioxo-4-[(2-phenylethyl)amino]butyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249539-59-1 CAPLUS
CN Pentanoic acid, 3-[[(2S)-4-amino-2-(1-methylethyl)-1,4-dioxobutyl]amino]-4-oxo-5-[[(2-phenylethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 249539-60-4 CAPLUS
CN Pentanoic acid, 3-[[(2S)-2-(1-methylethyl)-1,4-dioxo-4-[(2-phenylethyl)amino]butyl]amino]-4-oxo-5-[[(2-phenylethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249539-61-5 CAPLUS
CN Pentanoic acid, 5-[[[(7,7-dimethylbicyclo[2.2.1]hept-1-yl)methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-1,4-dioxo-4-[(2-phenylethyl)amino]butyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249539-64-8 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-1,4-dioxo-4-[(2-phenoxyethyl)amino]butyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249539-66-0 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-4-[methyl(2-phenylethyl)amino]-1,4-dioxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249539-67-1 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-1,4-dioxo-4-[(3-phenylpropyl)amino]butyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-4-[[3-(4-hydroxyphenyl)propyl]amino]-2-(1-methylethyl)-1,4-dioxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249539-76-2 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-4-[[2-(2-naphthalenyl)ethyl]amino]-1,4-dioxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 249539-77-3 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-4-[[2-(7-methyl-1H-indol-3-yl)ethyl]amino]-1,4-dioxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 249539-73-9 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-4-(hydroxyamino)-2-(1-methylethyl)-1,4-dioxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249539-74-0 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-4-[[2-(1H-indol-3-yl)ethyl]amino]-2-(1-methylethyl)-1,4-dioxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 249539-75-1 CAPLUS



RN 249539-79-5 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-4-[[2-(6-fluoro-1H-indol-3-yl)ethyl]amino]-2-(1-methylethyl)-1,4-dioxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—Me
—Me

RN 249539-85-3 CAPLUS
CN Pentanoic acid, 5-[[[(7,7-dimethylbicyclo[2.2.1]hept-1-yl)methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-1,4-dioxo-4-[(3-phenylpropyl)amino]butyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249539-88-6 CAPLUS
CN Pentanoic acid, 5-[[[(7,7-dimethylbicyclo[2.2.1]hept-1-yl)methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-4-[[2-(1-methyl-1H-indol-3-yl)ethyl]amino]-1,4-dioxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249539-90-0 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-1,4-dioxo-4-[[3-(4-pyridinyl)propyl]amino]butyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249539-91-1 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-



RN 249539-97-7 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-1,4-dioxo-4-[[3-(3-pyridinyl)propyl]amino]butyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249539-98-8 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-1,4-dioxo-4-[[3-(3-pyridinyl)propyl]amino]butyl]amino]-4-oxo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 249539-97-7
CMF C30 H44 N4 O8 S

Absolute stereochemistry.



yl]methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-1,4-dioxo-4-[[3-(4-pyridinyl)propyl]amino]butyl]amino]-4-oxo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 249539-90-0
CMF C30 H44 N4 O8 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 249539-93-3 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-1,4-dioxo-4-[[3-(2-quinolinyl)propyl]amino]butyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 249539-95-5 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-4-[[3-(2-naphthalenyl)propyl]amino]-1,4-dioxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 249540-01-0 CAPLUS
CN Pentanoic acid, 3-[[(2S)-4-[[2-(1H-benzimidazol-1-yl)ethyl]amino]-2-(1-methylethyl)-1,4-dioxobutyl]amino]-5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-4-oxo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 249540-00-9
CMF C31 H43 N5 O8 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 249540-03-2 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-4-[[2-(1-methyl-1H-indol-3-yl)ethyl]amino]-1,4-dioxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 249540-05-4 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-1,4-dioxo-4-[[2-(4-pyridinyl)ethyl]amino]butyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249540-06-5 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-1,4-dioxo-4-[[2-(4-pyridinyl)ethyl]amino]butyl]amino]-4-oxo-, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 249540-05-4
CMF C29 H42 N4 O8 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 249540-09-8 CAPLUS
CN Pentanoic acid, 3-[[(2S)-4-[[2-(5-acetyl-1H-indol-3-yl)ethyl]amino]-2-(1-methylethyl)-1,4-dioxobutyl]amino]-5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 249540-12-3 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-1,4-dioxo-4-[[2-(1H-tetrazol-5-yl)ethyl]amino]butyl]amino]-4-oxo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 249540-11-2
CMF C25 H39 N7 O8 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 249540-55-4 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[2-(1-methylethyl)-4-[methyl[2-(1-methyl-1H-indol-3-yl)ethyl]amino]-1,4-dioxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 249540-56-5 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[2-ethyl-1,4-dioxo-4-[(3-phenylpropyl)amino]butyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249540-57-6 CAPLUS
CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[2-ethyl-4-[[2-(1-methyl-1H-indol-3-yl)ethyl]amino]-1,4-dioxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



IT 249540-64-5P 249540-69-0P 249540-81-6P
249540-84-9P 249540-85-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of succinamide inhibitors of interleukin-1β converting enzyme)

RN 249540-64-5 CAPLUS

L7 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN Pentanoic acid, 3-[[2-methyl-1,4-dioxo-4-[(2-phenylethyl)amino]butyl]amino]-4-oxo-5-[[(2-phenylethyl)sulfonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 249540-69-0 CAPLUS

CN 2-Oxa-3,8,12-triazatridecan-13-oic acid, 12-[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]-6-(1-methylethyl)-4,7,10-trioxo-9-[2-oxo-2-(phenylmethoxy)ethyl]-1-phenyl-, 1,1-dimethylethyl ester, (6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249540-81-6 CAPLUS

CN Pentanoic acid, 5-[[(1,1-dimethylethoxy)carbonyl][[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-1,4-dioxo-4-[(2-phenoxyethyl)amino]butyl]amino]-4-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 249540-84-9 CAPLUS

CN Pentanoic acid, 5-[[(1,1-dimethylethoxy)carbonyl][[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-4-(1,1-dimethylethoxy)-2-(1-methylethyl)-1,4-dioxobutyl]amino]-4-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249540-85-0 CAPLUS

CN Pentanoic acid, 5-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-3-[[(2S)-2-(1-methylethyl)-1,4-dioxo-4-[(phenylmethoxy)amino]butyl]amino]-4-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:670116 CAPLUS

DOCUMENT NUMBER: 131:295568

TITLE: α- and β-Amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

INVENTOR(S): Vazques, Michael L.; Mueller, Richard A.; Talley, John J.; Getman, Daniel P.; Decrescenzo, Gary A.; Freskos, John N.; Bertenshaw, Deborah E.; Heintz, Robert M.

PATENT ASSIGNEE(S): G. D. Searle and Co., USA

SOURCE: U.S., 130 pp., Cont.-in-part of U. S. 204,827.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5968942	A	19991019	US 1994-294468	19940823
WO 9404492	A1	19940303	WO 1993-US7814	19930824
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 810209	A2	19971203	EP 1997-113434	19930824
EP 810209	A3	19981202		
EP 810209	B1	20020605		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
US 6060476	A	20000509	US 1994-204827	19940302
US 6248775	B1	20010619	US 1999-288080	19990408
US 2002052399	A1	20020502	US 2001-798255	20010305
US 6417387	B2	20020709		
US 2003191319	A1	20031009	US 2002-157019	20020530
US 6646010	B2	20031111		
US 6924286	B1	20050802	US 2003-633376	20030804

PRIORITY APPLN. INFO.:

US 1992-934984	B2	19920825
WO 1993-US7814	A2	19930824
US 1994-204827	A2	19940302
EP 1993-923714	A3	19930824
US 1993-110911	A2	19930824
US 1994-294468	A1	19940823
US 1999-288080	A1	19990408
US 2001-798255	A1	20010305
US 2002-157019	A1	20020530

OTHER SOURCE(S): MARPAT 131:295568

AB α- And β-Amino acid hydroxyethylamino sulfonamide compds. are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease, as well as effective in preventing the growth of retroviruses in a solution General and specific schemes for chemical synthesis of the sulfonamide-containing hydroxyethylamine inhibitor compds. are described. Seventy-eight such compds. were tested for cytotoxicity and antiviral efficacy (IC50, EC50, and TD50 values at the nanomolar level are tabulated).

IT **159005-89-7P 159005-90-0P 159005-91-1P 159005-92-2P 159005-95-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors)

L7 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 159005-89-7 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(methylsulfonyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159005-90-0 CAPLUS
CN 2-Thia-3,7,10-triazaundecan-11-oic acid, 9-(2-amino-2-oxoethyl)-5-hydroxy-3-(3-methylbutyl)-8-oxo-6-(phenylmethyl)-, phenylmethyl ester, 2,2-dioxide, (5R,6S,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159005-91-1 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 159005-92-2 CAPLUS
CN Carbamic acid, [(1S)-3-amino-1-[[[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-3-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159005-95-5 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-N4-methyl-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **159006-21-0P 159006-22-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(α- and β-amino acid hydroxyethylamino sulfonamides useful

L7 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
as retroviral protease inhibitors)
RN 159006-21-0 CAPLUS
CN Carbamic acid, [(1S)-3-amino-1-[[[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylsulfonyl)propylamino]propyl]amino]carbonyl]-3-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159006-22-1 CAPLUS
CN Carbamic acid, [(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-3-(methylamino)-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:799692 CAPLUS
DOCUMENT NUMBER: 130:38712
TITLE: Preparation of α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
INVENTOR(S): Vazquez, Michael L.; Mueller, Richard A.; Talley, John J.; Getman, Daniel; Decrescenzo, Gary A.; Freskos, John N.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: U.S., 67 pp., Cont.-in-part of U.S. Ser. No. 934,984, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5843946	A	19981201	US 1993-110911	19930824
EP 810209	A2	19971203	EP 1997-113434	19930824
EP 810209	A3	19981202		
EP 810209	B1	20020605		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
AT 172717	E	19981115	AT 1993-923714	19930824
ES 2123065	T3	19990101	ES 1993-923714	19930824
AT 218541	E	20020615	AT 1997-113434	19930824
PT 810209	T	20020930	PT 1997-113434	19930824
ES 2177868	T3	20021216	ES 1997-113434	19930824
WO 9506030	A1	19950302	WO 1994-US9139	19940823
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9476697	A1	19950321	AU 1994-76697	19940823
EP 715618	A1	19960612	EP 1994-927162	19940823
EP 715618	B1	19981216		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 174587	E	19990115	AT 1994-927162	19940823
ES 2127938	T3	19990501	ES 1994-927162	19940823
FI 9500650	A	19950214	FI 1995-650	19950214
FI 112471	B1	20031215		
US 5786483	A	19980728	US 1995-487662	19950607
US 5830897	A	19981103	US 1995-473698	19950607
US 6172082	B1	20010109	US 1995-476788	19950607
US 5744481	A	19980428	US 1997-845392	19970425
US 6248775	B1	20010619	US 1999-288080	19990408
US 6335460	B1	20020101	US 2000-510189	20000222
US 6472407	B1	20021029	US 2000-511005	20000222
US 6534493	B1	20030318	US 2000-694785	20001024
US 2002052399	A1	20020502	US 2001-798255	20010305
US 6417387	B2	20020709		
US 2003191319	A1	20031009	US 2002-157019	20020530
US 6646010	B2	20031111		
US 6924286	B1	20050802	US 2003-633376	20030804
PRIORITY APPLN. INFO.:			US 1992-934984 B2	19920825
			EP 1993-923714 A3	19930824
			US 1993-110911 A	19930824

	WO 1993-US7814	A2 19930824
	US 1994-204827	A 19940302
	US 1994-294468	A1 19940823
	WO 1994-US9139	W 19940823
	US 1995-476788	A1 19950607
	US 1995-485524	B1 19950607
	US 1999-288080	A1 19990408
	US 2001-798255	A1 20010305
	US 2002-157019	A1 20020530

OTHER SOURCE(S): MARPAT 130:38712

AB Amino acid hydroxyethylamino sulfonamide compds. P1NHCHR2CH(OH)CH2NR3SO2R4 [P1 = alkoxycarbonyl, aralkoxycarbonyl, alkanoyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkoxycarbonyl, heteroaralkoxycarbonyl, heteroaryloxycarbonyl, heteroaroyl; R2 = alkyl, aryl, cycloalkyl, cycloalkylalkyl, (un)substituted aralkyl; R3 = H, alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heteroaryl, heterocyclylalkyl, aryl, aralkyl, heteroaralkyl; R4 = alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, aryl, aralkyl] were preparation as retroviral protease inhibitors. Thus, N-[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-4-pyridinecarboxamide was prepared by amidation of isonicotinoyl chloride hydrochloride with 2R-hydroxy-3-[(2-methylpropyl)[(4-methoxyphenyl)sulfonyl]amino]-1S-(phenylmethyl)propylamine. Protease inhibitory data are tabulated.

IT **159005-89-7P 159005-91-1P 159005-92-2P**
159005-95-5P 159006-21-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors)

RN 159005-89-7 CAPLUS

CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(methylsulfonyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159005-91-1 CAPLUS

CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.



IT **159005-90-0P 159006-05-0P 159006-06-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors)

RN 159005-90-0 CAPLUS

CN 2-Thia-3,7,10-triazaundecan-11-oic acid, 9-(2-amino-2-oxoethyl)-5-hydroxy-3-(3-methylbutyl)-8-oxo-6-(phenylmethyl)-, phenylmethyl ester, 2,2-dioxide, (5R,6S,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159006-05-0 CAPLUS

CN Butanediamide, 2-amino-N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(methylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159005-92-2 CAPLUS

CN Carbamic acid, [(1S)-3-amino-1-[[[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-3-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159005-95-5 CAPLUS

CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-N4-methyl-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159006-21-0 CAPLUS

CN Carbamic acid, [(1S)-3-amino-1-[[[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylsulfonyl)propylamino]propyl]amino]carbonyl]-3-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 159006-06-1 CAPLUS

CN Butanediamide, 2-amino-N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:502547 CAPLUS
DOCUMENT NUMBER: 129:136097
TITLE: Preparation of heterocyclic sulfonamide inhibitors of aspartyl protease
INVENTOR(S): Tung, Roger D.; Murcko, Mark A.; Bhisetti, Govinda Rao
PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Incorporated, USA
SOURCE: U.S., 87 pp., Cont.-in-part of U.S. 5,585,397.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5783701	A	19980721	US 1995-393460	19950223
EP 885887	A2	19981223	EP 1998-113921	19930907
EP 885887	A3	19990203		
EP 885887	B1	20030528		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
US 5585397	A	19961217	US 1993-142327	19931124
US 5723490	A	19980303	US 1995-424819	19950419
US 5977137	A	19991102	US 1998-115394	19980714
US 6392046	B1	20020521	US 1999-409808	19990930
US 2003064977	A1	20030403	US 2002-94763	20020308
US 6720335	B2	20040413		
US 2004167116	A1	20040826	US 2004-786997	20040224
PRIORITY APPLN. INFO.:			US 1992-941982	B2 19920908
			US 1993-142327	A2 19931124
			EP 1993-921428	A3 19930907
			WO 1993-US8458	W 19930907
			US 1995-393460	B2 19950223
			US 1998-115394	A3 19980714
			US 1999-409808	A3 19990930
			US 2002-94763	A1 20020308

OTHER SOURCE(S): MARPAT 129:136097
GI



I



II

AB The title compds. I [A = H, -Ht, -R1Ht, (un)substituted -R1-alk(en)yl; R1 = CO, SO2, COCO, OCO, OSO2, NR2SO2, NR2CO, NR2COCO; Ht = (un)substituted

L7 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

IT 160230-05-7P 160230-06-8P 160230-07-9P
160230-08-0P 160230-09-1P 160230-10-4P
160230-11-5P 160230-12-6P 160230-13-7P
160230-14-8P 160230-16-0P 160230-17-1P
160230-18-2P 160230-19-3P 160230-20-6P
160230-21-7P 160230-22-8P 160230-23-9P
160230-24-0P 160230-50-2P 160231-93-6P
160231-96-9P 160333-42-6P 160333-43-7P
160333-44-8P 160333-45-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic sulfonamide derivs. as inhibitors of HIV aspartyl protease)

RN 160230-05-7 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylmethyl)(phenylsulfonyl)amino]propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-06-8 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[3-(acetylamino)-4-fluorophenyl]sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-07-9 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

cycloalk(en)yl, aryl, (benzo)heterocyclyl; R2 = H, alkyl, -alkyl-R7; B = NR2C(R3)2CO; n = 0, 1; R3 = (un)substituted alk(en)yl or cycloalk(en)yl; n = 1, 2; D, D' = R7, (un)substituted alk(en)yl or cycloalk(en)yl; R7 = (un)substituted Ph, carbocyclyl, or heterocyclyl; E = Ht, -O-Ht, -Ht-Ht, OR3, NR2R3, (un)substituted alk(en)yl or carbocyclyl; R4 = OR2, CONHR2, SO2NHR2, halo, NR2COR2, cyano] are prepd. as inhibitors of HIV aspartyl protease. The invention also relates to pharmaceutical compns. comprising these compds. The compds. and pharmaceutical compns. are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity. The invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the invention compds., and to methods for screening compds. for anti-HIV activity. Prepns. of almost 200 compds. are described, and some of these plus addnl. compds. are claimed. Some of the compds., e.g., II, inhibit HIV replication (IC90) in CCRM-CEM cells in vitro at concns. of ≤ 100 nM.

IT 186463-21-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of heterocyclic sulfonamide derivs. as inhibitors
of HIV aspartyl protease)

RN 186463-21-8 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[3-(aminosulfonyl)phenyl]sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 160230-14-8
CMF C37 H38 N6 O8 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L7 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 160230-08-0 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylmethyl)[[3-(trifluoromethyl)phenyl]sulfonyl]amino]propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-09-1 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[2-(acetylamino)-4-methyl-5-thiazolyl]sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-10-4 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[[[5-(3-isoxazolyl)-2-thienyl]sulfonyl](phenylmethyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-11-5 CAPLUS
CN Benzoic acid, 3-[[[(2R,3S)-3-[[(2S)-4-amino-1,4-dioxo-2-[(2-quinolinylcarbonyl)amino]butyl]amino]-2-hydroxy-4-phenylbutyl](phenylmethyl)amino]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-12-6 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(methylsulfonyl)(phenylmethyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-13-7 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[(2,1,3-benzoxadiazol-4-ylsulfonyl)(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-18-2 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[(4-fluorophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-19-3 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[4-(acetylamino)-3-fluorophenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-20-6 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[3-(acetylamino)-4-fluorophenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-14-8 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[3-(aminosulfonyl)phenyl]sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-16-0 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[5-(2-pyridinyl)-2-thienyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-17-1 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[4-(phenylsulfonyl)-2-thienyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-21-7 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[4-(acetylamino)phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-22-8 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[2-(acetylamino)-4-methyl-5-thiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-23-9 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[3-(acetylamino)phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-24-0 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[(2,1,3-benzoxadiazol-4-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-50-2 CAPLUS
CN Butanediamide, N-[(1S,2R)-3-[[[4-(acetylamino)phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160231-93-6 CAPLUS
CN Butanediamide, N1-[(1S,2S)-2-hydroxy-3-[[[5-(3-isoxazolyl)-2-thienyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160333-44-8 CAPLUS
CN Butanediamide, N1-[(1S,2S)-3-[[[4-(acetylamino)phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160333-45-9 CAPLUS
CN Butanediamide, N1-[(1S,2S)-3-[[[3-(acetylamino)-4-fluorophenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



RN 160231-96-9 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[4-(acetylamino)-3-fluorophenyl]sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160333-42-6 CAPLUS
CN Butanediamide, N1-[(1S,2S)-3-[[[4-(acetylamino)-3-fluorophenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160333-43-7 CAPLUS
CN Butanediamide, N1-[(1S,2S)-3-[(2,1,3-benzoxadiazol-4-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:501276 CAPLUS
DOCUMENT NUMBER: 129:170511
TITLE: Use of quinoxalines in three-way combinations with protease inhibitors and reverse transcriptase inhibitors as a drug for treating AIDS and/or HIV infections
INVENTOR(S): Paessens, Arnold; Blunck, Martin; Riess, Guenter; Kleim, Joerg-Peter; Roesner, Manfred
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 22 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19703131	A1	19980730	DE 1997-19703131	19970129
CA 2278773	AA	19980730	CA 1998-2278773	19980115
WO 9832442	A1	19980730	WO 1998-EP197	19980115
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9860940	A1	19980818	AU 1998-60940	19980115
EP 977570	A1	20000209	EP 1998-905297	19980115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
BR 9807523	A	20000321	BR 1998-7523	19980115
JP 2001511124	T2	20010807	JP 1998-531540	19980115
ZA 9800679	A	19980805	ZA 1998-679	19980128
NO 9903670	A	19990910	NO 1999-3670	19990728
MX 9907077	A	20000531	MX 1999-7077	19990729

PRIORITY APPLN. INFO.: DE 1997-19703131 A 19970129
WO 1998-EP197 W 19980115

AB Quinoxaline derivs. in combination with protease inhibitors and reverse transcriptase inhibitors inhibited HIV replication in human lymphocytes. Such 3-way combinations are synergistic and may be used to treat persons with HIV infections or AIDS.

IT 181703-69-5, AM 11686
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(AIDS and HIV infections treatment by combinations of quinoxalines and reverse transcriptase inhibitors with protease inhibitors such as)

RN 181703-69-5 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(methylsulfonyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L7 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:9928 CAPLUS
DOCUMENT NUMBER: 126:144117
TITLE: Preparation of sulfonamide inhibitors of aspartyl protease
INVENTOR(S): Tung, Roger D.; Murcko, Mark A.; Bhisetti, Govinda R.
PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Incorporated, USA
SOURCE: U.S., 87 pp., Cont.-in-part of U.S. Ser. No. 941,982, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5585397	A	19961217	US 1993-142327	19931124
WO 9405639	A1	19940317	WO 1993-US8458	19930907
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 885887	A2	19981223	EP 1998-113921	19930907
EP 885887	A3	19990203		
EP 885887	B1	20030528		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
US 5783701	A	19980721	US 1995-393460	19950223
US 5723490	A	19980303	US 1995-424819	19950419
US 5856353	A	19990105	US 1995-477937	19950607
US 6372778	B1	20020416	US 1995-484326	19950607
US 5977137	A	19991102	US 1998-115394	19980714
US 6004957	A	19991221	US 1998-121008	19980722
US 6392046	B1	20020521	US 1999-409808	19990930
US 2003064977	A1	20030403	US 2002-94763	20020308
US 6720335	B2	20040413		
US 2003069222	A1	20030410	US 2002-94790	20020308
US 2004167116	A1	20040826	US 2004-786997	20040224

PRIORITY APPLN. INFO.:

US 1992-941982	B2	19920908
WO 1993-US8458	W	19930907
EP 1993-921428	A3	19930907
US 1993-142327	A2	19931124
US 1995-393460	B2	19950223
US 1995-484326	A3	19950607
US 1998-115394	A3	19980714
US 1999-409808	A3	19990930
US 2002-94763	A1	20020308

OTHER SOURCE(S): MARPAT 126:144117
GI



I

L7 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

AB The title compds. I [A = 3-tetrahydrofuryloxycarbonyl; D' = (un)substituted alkyl; E = (un)substituted aryl] are prepared This invention also relates to pharmaceutical compns. comprising these compds. The compds. and pharmaceutical compns. of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as antiviral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compds. of this invention and methods for screening compds. for anti-HIV activity. The title compds. inhibit HIV replication at concentration of ≤ 100 nM.

IT **160230-05-7P 160230-06-8P 160230-07-9P**
160230-08-0P 160230-09-1P 160230-10-4P
160230-11-5P 160230-12-6P 160230-13-7P
160230-14-8P 160230-16-0P 160230-17-1P
160230-18-2P 160230-19-3P 160230-20-6P
160230-21-7P 160230-22-8P 160230-23-9P
160230-24-0P 160230-50-2P 160231-93-6P
160231-96-9P 160333-42-6P 160333-43-7P
160333-44-8P 160333-45-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamide inhibitors of aspartyl protease)

RN 160230-05-7 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylmethyl)(phenylsulfonyl)amino]propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-06-8 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[3-(acetylamino)-4-fluorophenyl]sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-07-9 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-08-0 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylmethyl)[[3-(trifluoromethyl)phenyl]sulfonyl]amino]propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-09-1 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[2-(acetylamino)-4-methyl-5-thiazolyl]sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-10-4 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[[[5-(3-isoxazolyl)-2-thienyl]sulfonyl](phenylmethyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-11-5 CAPLUS
CN Benzoic acid, 3-[[[(2R,3S)-3-[[(2S)-4-amino-1,4-dioxo-2-[(2-quinolinylcarbonyl)amino]butyl]amino]-2-hydroxy-4-phenylbutyl](phenylmethyl)amino]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-12-6 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(methylsulfonyl)(phenylmethyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-17-1 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[4-(phenylsulfonyl)-2-thienyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-18-2 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[(4-fluorophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-19-3 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[4-(acetylamino)-3-fluorophenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-13-7 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[(2,1,3-benzoxadiazol-4-ylsulfonyl)(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-14-8 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[3-(aminosulfonyl)phenyl]sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-16-0 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[5-(2-pyridinyl)-2-thienyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-20-6 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[3-(acetylamino)-4-fluorophenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-21-7 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[4-(acetylamino)phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-22-8 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[2-(acetylamino)-4-methyl-5-thiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-23-9 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[3-(acetylamino)phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-24-0 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[(2,1,3-benzoxadiazol-4-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-50-2 CAPLUS
CN Butanediamide, N-[(1S,2R)-3-[[[4-(acetylamino)phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160231-93-6 CAPLUS
CN Butanediamide, N1-[(1S,2S)-2-hydroxy-3-[[[5-(3-isoxazolyl)-2-thienyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160231-96-9 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[4-(acetylamino)-3-fluorophenyl]sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160333-42-6 CAPLUS
CN Butanediamide, N1-[(1S,2S)-3-[[[4-(acetylamino)-3-fluorophenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160333-43-7 CAPLUS
CN Butanediamide, N1-[(1S,2S)-3-[(2,1,3-benzoxadiazol-4-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160333-44-8 CAPLUS
CN Butanediamide, N1-[(1S,2S)-3-[[[4-(acetylamino)phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160333-45-9 CAPLUS
CN Butanediamide, N1-[(1S,2S)-3-[[[3-(acetylamino)-4-fluorophenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 186463-21-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonamide inhibitors of aspartyl protease)

RN 186463-21-8 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[3-(aminosulfonyl)phenyl]sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 160230-14-8
CMF C37 H38 N6 O8 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L7 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:601709 CAPLUS
DOCUMENT NUMBER: 125:238651
TITLE: Use of quinoxalines and protease inhibitors in a composition for the treatment of AIDS and/or HIV infections
INVENTOR(S): Paessens, Arnold; Blunck, Martin; Riess, Guenther; Kleim, Joerg-Peter; Roesner, Manfred
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 728481	A2	19960828	EP 1996-102129	19960214
EP 728481	A3	19980708		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
DE 19506742	A1	19960829	DE 1995-19506742	19950227
AU 9645615	A1	19960905	AU 1996-45615	19960220
AU 710158	B2	19990916		
CA 2170222	AA	19960828	CA 1996-2170222	19960223
FI 9600850	A	19960828	FI 1996-850	19960223
JP 08245392	A2	19960924	JP 1996-60286	19960223
IL 117247	A1	20001031	IL 1996-117247	19960223
NO 9600775	A	19960828	NO 1996-775	19960226
ZA 9601516	A	19960903	ZA 1996-1516	19960226
BR 9600809	A	19971223	BR 1996-809	19960226
CN 1141196	A	19970129	CN 1996-102709	19960227

PRIORITY APPLN. INFO.: DE 1995-19506742 A 19950227
OTHER SOURCE(S): MARPAT 125:238651
GI



I

AB Combinations of a quinoxaline derivative [I; R1 = halo, OH, NO2, (substituted) amino, N3, CF3, CF3O, C1-8 alkyl, CN, (substituted) Ph, N-heterocyclyl, etc.; R2, R5 = H, OH, C1-6 alkoxy, aryloxy, C1-6 acyloxy, CN, (substituted) amino, (substituted) C1-8 alkyl, (substituted) C2-8 alkenyl, (substituted) C3-8 alkynyl, (substituted) C3-8 cycloalk(en)yl, etc.; R3, R4 = H, (substituted) C1-8 alkyl, (substituted) C2-8 alkenyl, (substituted) C3-8 cycloalk(en)yl, (substituted)aryl, etc.; or R3R4 or R3R5 complete a (substituted) ring; X = O, S, Se, NR2; n = 0-4] and a peptidomimetic protease inhibitor are useful for treatment of HIV infections and AIDS. Thus, I [R1 = 6-MeO, R2 = R3 = H, R4 = (S)-MeSCH2, R5 = i-PrO2C, X = S] (0.7-6 nM) and saquinavir (6-50 nM) synergistically inhibited syncytium formation in HIV-infected human lymphocytes in vitro.
IT 181703-69-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L7 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of quinoxalines and protease inhibitors for treatment of AIDS and HIV infections)
RN 181703-69-5 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(methylsulfonyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:47171 CAPLUS
DOCUMENT NUMBER: 124:193129
TITLE: Determination of protein binding by in vitro charcoal adsorption
AUTHOR(S): Yuan, Jinhua; Yang, Dai Chang; Birkmeier, Jill; Stolzenbach, James
CORPORATE SOURCE: Pharmacokinetics, Bioanalytical and Radiochemistry Function, G. D. Searle Research and Development, Skokie, IL, 60077, USA
SOURCE: Journal of Pharmacokinetics and Biopharmaceutics (1995), 23(1), 41-55
CODEN: JPBPBJ; ISSN: 0090-466X
PUBLISHER: Plenum
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Certain compds. such as SC-52151 have extensive nonspecific adsorption to the ultrafiltration devices or to dialysis membranes and therefore can not be measured by the conventional ultrafiltration or equilibrium dialysis methods. A new method based on charcoal adsorption was developed to overcome this difficulty. Unlike many conventional methods, which are based on the separation of free drug from bound drug under equilibrium conditions, the new method is operated under nonequil. conditions and involves measuring the time course of decline of the percentage of bound drug remaining in plasma while the free drug is being removed by charcoal adsorption. Theor. aspects of the method and the data processing procedure are presented. SC-98A, a compound with minimal nonspecific adsorption to the ultrafiltration membrane, was used to demonstrate the applicability of this method against the ultrafiltration method. Using this method, the protein binding of SC-52151 in human plasma at 1.0 μg/mL was determined to be in the range of 91.4-97.7% at room temperature
IT 157445-98-2, SC 98A
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(protein binding determination by in vitro charcoal adsorption)
RN 157445-98-2 CAPLUS
CN Butanoic acid, 4-[[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:964989 CAPLUS
DOCUMENT NUMBER: 124:176937
TITLE: N-[(Succinoylamino)hydroxypropyl]sulfonamides useful as retroviral protease inhibitors
INVENTOR(S): Vazquez, Michael L.; Mueller, Richard A.; Talley, John J.; Getman, Daniel; Decrescenzo, Gary A.; Freskos, John N.
PATENT ASSIGNEE(S): G. D. Searle and Co., USA
SOURCE: U.S., 32 pp. Cont.-in-part of U.S. Ser. No. 935,490, abandoned
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5463104	A	19951031	US 1993-110912	19930824
AT 154800	E	19970715	AT 1993-920213	19930824
ES 2103488	T3	19970916	ES 1993-920213	19930824
US 5714605	A	19980203	US 1995-541350	19951010
US 5760076	A	19980602	US 1995-541747	19951010
US 6022994	A	20000208	US 1998-41016	19980312
US 6313345	B1	20011106	US 1999-419816	19991018
US 2002137942	A1	20020926	US 2001-884462	20010620
US 6469207	B2	20021022		
US 2003220508	A1	20031127	US 2002-237184	20020909
US 6727282	B2	20040427		
US 2005004043	A1	20050106	US 2004-784916	20040224

PRIORITY APPLN. INFO.: US 1992-935490 B2 19920825
US 1993-110912 A3 19930824
US 1995-541350 A1 19951010
US 1995-541747 A1 19951010
US 1998-41016 A1 19980312
US 1999-419816 A1 19991018
US 2001-884462 A1 20010620
US 2002-237184 A1 20020909
OTHER SOURCE(S): MARPAT 124:176937
GI



I



II

AB Succinoylamino hydroxyethylamino sulfonamide compds. I or a pharmaceutically acceptable salt or ester thereof, wherein p represents 0, 1 or 2; n represents either 0 or 1; X' represents N(R34) or O; or R33X' represents cycloalkyl or aryl radicals; Y and Y' each independently represent O or S; R1, R30, R31 and R32 each independently represent hydrogen, OH, (CH2)C(O)CH3, CH2SO2NH2, CO2CH3, CONHCH3, CON(CH3)2, CH2C(O)NHCH3, CH2C(O)N(CH3)2, CONH2, C(CH3)2(SH), C(CH3)2(SCH3), C(CH3)2[S(O)CH3], C(CH3)2[S(O)2CH3], alkyl, haloalkyl, alkenyl, alkynyl, aralkyl or cycloalkyl radicals, or the side chain of the amino acid asparagine, 5-Me cysteine or the corresponding sulfoxide or sulfone derivs. thereof, leucine, isoleucine, allo-isoleucine, tert-leucine, phenylalanine, ornithine, alanine, norleucine, glutamine, valine, threonine, serine, O-alkyl serine, aspartic acid, β-cyanoalanine or allothreonine; or R30 and R32 together with the carbon atoms to which they are attached form a cycloalkyl radical; R2 = e.g., alkyl, aryl, cycloalkyl; R3, R33, R34 = e.g., H, alkyl, haloalkyl; R4 = e.g., alkyl, haloalkyl, alkenyl; R6 = H, alkyl; are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. Thus, e.g., butanediamide II was prepared by coupling of benzyl (R)-2,2,3-trimethylsuccinate (preparation given) with 2(R)-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1(S)-(phenylmethyl)propylamine (preparation given) followed by benzyl ester hydrogenolysis and amidation, and exhibited IC50 = 2 nM for inhibition of HIV protease.

IT **157445-96-0P 157445-97-1P 157445-98-2P**
157445-99-3P 157446-00-9P 157446-02-1P
157446-03-2P 157446-04-3P 157446-05-4P
157446-06-5P 157446-07-6P 157446-08-7P
157446-09-8P 157474-44-7P 173590-71-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(N-[(succinoylamino)hydroxypropyl]sulfonamides useful as retroviral protease inhibitors)

RN 157445-96-0 CAPLUS
CN Butanediamide, N4-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-2,2,3-trimethyl-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157445-97-1 CAPLUS
CN Butanoic acid, 4-[[2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, phenylmethyl ester, [1S-[1R*(S*),2S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157445-98-2 CAPLUS
CN Butanoic acid, 4-[[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157445-99-3 CAPLUS
CN Butanoic acid, 4-[[2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, phenylmethyl ester, [1S-[1R*(S*),2S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157446-00-9 CAPLUS
CN Butanoic acid, 4-[[2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, [1S-[1R*(S*),2S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157446-02-1 CAPLUS
CN Butanoic acid, 4-[[2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-

methylpropyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, phenylmethyl ester, [1S-[1R*(S*),2S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157446-03-2 CAPLUS
CN Butanoic acid, 4-[[2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, [1S-[1R*(S*),2S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157446-04-3 CAPLUS
CN Butanediamide, N4-[(1S,2R)-2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-2,2,3-trimethyl-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157446-05-4 CAPLUS
CN Butanediamide, N4-[(1S,2R)-2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](3-methylbutyl)amino]-1-(phenylmethyl)propyl]-2,2,3-trimethyl-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157446-06-5 CAPLUS
CN Butanoic acid, 4-[[2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](3-methylbutyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, phenylmethyl ester, [1S-[1R*(S*),2S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157446-07-6 CAPLUS
CN Butanediamide, N4-[(1S,2R)-3-[[(4-fluorophenyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2,2,3-trimethyl-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157446-08-7 CAPLUS
CN Butanoic acid, 4-[[3-[[(4-fluorophenyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, phenylmethyl ester, [1S-[1R*(S*),2S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 157446-09-8 CAPLUS
CN Butanoic acid, 4-[[3-[[(4-fluorophenyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, [1S-[1R*(S*),2S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157474-44-7 CAPLUS
CN Butanoic acid, 4-[[2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](3-methylbutyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, [1S-[1R*(S*),2S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173590-71-1 CAPLUS
CN Butanediamide, N4-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-2,2,3-trimethyl-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:871984 CAPLUS
DOCUMENT NUMBER: 123:279761
TITLE: Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
INVENTOR(S): Vazquez, Michael L.; Mueller, Richard A.; Talley, John J.; Getman, Daniel P.; Decrescenzo, Gary A.; Freskos, John N.; Bertenshaw, Deborah E.; Heintz, Robert M.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA; Monsanto Co.
SOURCE: PCT Int. Appl., 255 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9506030	A1	19950302	WO 1994-US9139	19940823
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5843946	A	19981201	US 1993-110911	19930824
US 6060476	A	20000509	US 1994-204827	19940302
AU 9476697	A1	19950321	AU 1994-76697	19940823
EP 715618	A1	19960612	EP 1994-927162	19940823
EP 715618	B1	19981216		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 6046190	A	20000404	US 1996-586866	19960124
PRIORITY APPLN. INFO.:			US 1993-110911 A	19930824
			US 1994-204827 A	19940302
			US 1992-934984 B2	19920825
			WO 1993-US7814 A2	19930824
			US 1994-204872 B2	19940302
			WO 1994-US9139 W	19940823

OTHER SOURCE(S): MARPAT 123:279761

AB Hyroxethylamino sulfonamide compds. AC(:Y)NR6CHR2CHOHCH2NR3S(:O)$_x$R4 [I: R2=(substituted)alkyl, aryl, cycloalkyl, cycloalkylalkyl, aralkyl; R3=H; R3,R4=R2, alkenyl, alkynyl, heterocycloalkyl, -aryl, -aralkyl, -cycloalkyalkyl; R6=H, alkyl; x=1,2; Y=O, S; A=RO, R; R=alkyl, alkenyl; (hetero)aryl, cycloalkyl, cycloalkylalkyl, aralkyl, NH2, mono- or disubstituted amino, etc.] are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. Many inhibitors were prepared by (1) preparing an N-protected amino epoxide and (2) reacting this with an amine and (3) preparing a sulfonamide by reacting with a sulfonyl chloride or sulfonyl anhydride in the presence of an acid scavenger. The amino function of the sulfonamide was then (4) deprotected and (5) reacted with a carboxylate. In vitro HIV protease assays with these compds. revealed inhibitors with IC50's as low as 1.4 nM, e.g. [1S-[1R*(S*),2S*]]-I (A=p-MeOC6H4CH2OCONHCH2CHMe; Y=O; R6=H; R2=benzyl; R3=3-methylbutyl; x=2; R4=phenyl).

IT **159005-89-7P 159005-91-1P 159005-95-5P**
159006-21-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(hydroxyethylamino sulfonamides useful as retroviral protease

inhibitors)

RN 159005-89-7 CAPLUS

CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(methylsulfonyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159005-91-1 CAPLUS

CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159005-95-5 CAPLUS

CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-N4-methyl-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 159005-90-0P 159006-05-0P 159006-22-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(hydroxyethylamino sulfonamides useful as retroviral protease inhibitors)

RN 159005-90-0 CAPLUS

CN 2-Thia-3,7,10-triazaundecan-11-oic acid, 9-(2-amino-2-oxoethyl)-5-hydroxy-3-(3-methylbutyl)-8-oxo-6-(phenylmethyl)-, phenylmethyl ester, 2,2-dioxide, (5R,6S,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159006-05-0 CAPLUS

CN Butanediamide, 2-amino-N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(methylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 159006-21-0 CAPLUS

CN Carbamic acid, [(1S)-3-amino-1-[[[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylsulfonyl)propylamino]propyl]amino]carbonyl]-3-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 159005-92-2 159006-06-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(hydroxyethylamino sulfonamides useful as retroviral protease inhibitors)

RN 159005-92-2 CAPLUS

CN Carbamic acid, [(1S)-3-amino-1-[[[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-3-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159006-06-1 CAPLUS

CN Butanediamide, 2-amino-N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159006-22-1 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-3-(methylamino)-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:352211 CAPLUS
DOCUMENT NUMBER: 122:204547
TITLE: Inhibitors of HIV-1 Protease Containing the Novel and Potent (R)-(Hydroxyethyl)sulfonamide Isostere
AUTHOR(S): Vazquez, Michael L.; Bryant, Martin L.; Clare, Michael; DeCrescenzo, Gary A.; Doherty, Elizabeth M.; Freskos, John N.; Getman, Daniel P.; Houseman, Kathryn A.; Julien, Janet A.; et al.
CORPORATE SOURCE: Searle Discovery Research, Skokie, IL, 60077, USA
SOURCE: Journal of Medicinal Chemistry (1995), 38(4), 581-4
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 122:204547

AB The authors have prepared and tested a series of novel and highly potent HIV-1 protease inhibitors based on the (R)-(hydroxyethyl)sulfonamide isostere. The isotere exhibits enhanced potency relative to the previously reported (hydroxyethyl)urea isotere. The preferred stereochem. for the critical hydroxyl group is R. X-ray crystallog. studies show that these inhibitors bind to the protease in an extended fashion with one of the sulfonamide oxygens forming a hydrogen bond to the key structural water mol. Some of the compds. showed excellent antiviral activity in vitro.

IT **159005-90-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(inhibitors of HIV-1 protease containing novel and potent (R)-(hydroxyethyl)sulfonamide isostere in relation to antiviral activity)

RN 159005-90-0 CAPLUS

CN 2-Thia-3,7,10-triazaundecan-11-oic acid, 9-(2-amino-2-oxoethyl)-5-hydroxy-3-(3-methylbutyl)-8-oxo-6-(phenylmethyl)-, phenylmethyl ester, 2,2-dioxide, (5R,6S,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **159005-91-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(inhibitors of HIV-1 protease containing novel and potent (R)-(hydroxyethyl)sulfonamide isostere in relation to antiviral activity)

RN 159005-91-1 CAPLUS

L7 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **159006-06-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(inhibitors of HIV-1 protease containing novel and potent (R)-(hydroxyethyl)sulfonamide isostere in relation to antiviral activity)

RN 159006-06-1 CAPLUS

CN Butanediamide, 2-amino-N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **159005-89-7P 159005-92-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitors of HIV-1 protease containing novel and potent (R)-(hydroxyethyl)sulfonamide isostere in relation to antiviral activity)

RN 159005-89-7 CAPLUS

CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(methylsulfonyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159005-92-2 CAPLUS

CN Carbamic acid, [(1S)-3-amino-1-[[[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-3-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:293723 CAPLUS
DOCUMENT NUMBER: 122:81141
TITLE: Preparation of heterocyclylarylsulfonamide inhibitors of HIV-aspartyl protease
INVENTOR(S): Tung, Roger D.; Murcko, Mark A.; Bhisetti, Govinda Rao
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 291 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9405639	A1	19940317	WO 1993-US8458	19930907
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
LT 3302	B	19950626	LT 1993-917	19930901
IL 106927	A1	20010111	IL 1993-106927	19930906
EP 659181	A1	19950628	EP 1993-921428	19930907
EP 659181	B1	19990407		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08501299	T2	19960213	JP 1994-507525	19930907
HU 71892	A2	19960228	HU 1995-685	19930907
AU 691160	B2	19980514	AU 1993-48520	19930907
AU 9348520	A1	19940329		
EP 885887	A2	19981223	EP 1998-113921	19930907
EP 885887	A3	19990203		
EP 885887	B1	20030528		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
AT 178598	E	19990415	AT 1993-921428	19930907
ES 2131589	T3	19990801	ES 1993-921428	19930907
RU 2135496	C1	19990827	RU 1995-109928	19930907
SK 281360	B6	20010212	SK 1995-293	19930907
CZ 289475	B6	20020116	CZ 1995-587	19930907
CA 2143208	C	20030107	CA 1993-2143208	19930907
AT 241602	E	20030615	AT 1998-113921	19930907
PL 185635	B1	20030630	PL 1993-307858	19930907
RO 118747	B1	20031030	RO 1995-479	19930907
PT 885887	T	20031031	PT 1998-113921	19930907
ES 2200243	T3	20040301	ES 1998-113921	19930907
CN 1087347	A	19940601	CN 1993-117370	19930908
CN 1061339	B	20010131		
ZA 9308470	A	19940620	ZA 1993-8470	19931112
US 5585397	A	19961217	US 1993-142327	19931124
FI 9501059	A	19950418	FI 1995-1059	19950307
NO 9500876	A	19950508	NO 1995-876	19950307
NO 303444	B1	19980713		
HK 1012631	A1	20000623	HK 1998-113971	19981217
HK 1023561	A1	20040716	HK 2000-100689	19981217
PRIORITY APPLN. INFO.:			US 1992-941982 A2	19920908
			EP 1993-921428 A3	19930907
			WO 1993-US8458 W	19930907

OTHER SOURCE(S): MARPAT 122:81141
GI



I



II

AB Title compds. A(B)xNHCH(D)CH(OH)CH2N(D')SO2E (A = H, Het, R1-Het, (substituted)R1-C1-6 alkyl, (substituted) R1-C2-6 alkenyl wherein R1 = CO, SO2, COCO, O2C, etc., Het = C5-7 cycloalkyl, C5-7 cycloalkenyl, C6-10 aryl, (substituted) 5-7-membered heterocyclyl; R2 = H, (Ar)-C1-3 alkyl; B = NR2CR3CO, null wherein R3 = H, (substituted)Het or C1-6 alkyl or C2-6 alkenyl or C3-6 cycloalkyl or C5-6 cycloalkenyl; x = 0,1; D, D' = Ar, (substituted) C1-4 alkyl wherein Ar = Ph, (substituted) 3-6-membered carbocyclyl or 5-6-membered heterocyclyl; E = Het-O, Het-Het, (substituted) C1-6 alkyl or C2-6 alkenyl, C3-6 carbocyclyl) useful also against viral infection of HIV-2, HIV-2, or HTLV, are prepared 4,3-(AcNH)FC6H3SO2Cl and syn-I (A = quinolin-2-ylcarbonyl, D' = Me2CHCH2) (preparation given) in CH2Cl2 was treated with F3CCO2H followed by NaHCO3 and 4-FC6H4SO2Cl to give the title compound II which inhibited HIV-1 protease with IC50 of <0.1 nM.

IT **160230-05-7P 160230-06-8P 160230-07-9P**
160230-08-0P 160230-09-1P 160230-10-4P
160230-11-5P 160230-12-6P 160230-13-7P
160230-14-8P 160230-16-0P 160230-17-1P
160230-18-2P 160230-19-3P 160230-20-6P
160230-21-7P 160230-22-8P 160230-23-9P
160230-24-0P 160230-50-2P 160231-93-6P
160231-96-9P 160333-42-6P 160333-43-7P
160333-44-8P 160333-45-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of as HIV-1 protease inhibitor)

RN 160230-05-7 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylmethyl)(phenylsulfonyl)amino]propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-06-8 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[(3-(acetylamino)-4-fluorophenyl]sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-07-9 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-08-0 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylmethyl)[[3-(trifluoromethyl)phenyl]sulfonyl]amino]propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-09-1 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[2-(acetylamino)-4-methyl-5-thiazolyl]sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-10-4 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[[[5-(3-isoxazolyl)-2-thienyl]sulfonyl](phenylmethyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-11-5 CAPLUS
CN Benzoic acid, 3-[[[(2R,3S)-3-[[(2S)-4-amino-1,4-dioxo-2-[(2-quinolinylcarbonyl)amino]butyl]amino]-2-hydroxy-4-phenylbutyl](phenylmethyl)amino]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-12-6 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(methylsulfonyl)(phenylmethyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-13-7 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[(2,1,3-benzoxadiazol-4-ylsulfonyl)(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-14-8 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[3-(aminosulfonyl)phenyl]sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-16-0 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[5-(2-pyridinyl)-2-thienyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-17-1 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[4-(phenylsulfonyl)-2-thienyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-18-2 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[(4-fluorophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-22-8 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[2-(acetylamino)-4-methyl-5-thiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-23-9 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[3-(acetylamino)phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-24-0 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[(2,1,3-benzoxadiazol-4-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-19-3 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[4-(acetylamino)-3-fluorophenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-20-6 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[3-(acetylamino)-4-fluorophenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-21-7 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[4-(acetylamino)phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160230-50-2 CAPLUS
CN Butanediamide, N-[(1S,2R)-3-[[[4-(acetylamino)phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160231-93-6 CAPLUS
CN Butanediamide, N1-[(1S,2S)-2-hydroxy-3-[[[5-(3-isoxazolyl)-2-thienyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160231-96-9 CAPLUS
CN Butanediamide, N1-[(1S,2R)-3-[[[4-(acetylamino)-3-fluorophenyl]sulfonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160333-42-6 CAPLUS
CN Butanediamide, N1-[(1S,2S)-3-[[[4-(acetylamino)-3-fluorophenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160333-43-7 CAPLUS
CN Butanediamide, N1-[(1S,2S)-3-[(2,1,3-benzoxadiazol-4-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160333-44-8 CAPLUS
CN Butanediamide, N1-[(1S,2S)-3-[[[4-(acetylamino)phenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160333-45-9 CAPLUS
CN Butanediamide, N1-[(1S,2S)-3-[[[3-(acetylamino)-4-fluorophenyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ACCESSION NUMBER: 1994:701324 CAPLUS
DOCUMENT NUMBER: 121:301324
TITLE: Preparation of hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
INVENTOR(S): Vazquez, Michael L.; Mueller, Richard A.; Talley, John J.; Getman, Daniel; Decrescenzo, Gary A.; Freskos, John N.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA; Monsanto Co.
SOURCE: PCT Int. Appl., 198 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9404492	A1	19940303	WO 1993-US7814	19930824
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 656887	A1	19950614	EP 1993-923714	19930824
EP 656887	B1	19981028		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 08501288	T2	19960213	JP 1994-506530	19930824
JP 3657002	B2	20050608		
AU 680635	B2	19970807	AU 1994-53474	19930824
AU 9453474	A1	19940315		
EP 810209	A2	19971203	EP 1997-113434	19930824
EP 810209	A3	19981202		
EP 810209	B1	20020605		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
AT 172717	E	19981115	AT 1993-923714	19930824
ES 2123065	T3	19990101	ES 1993-923714	19930824
RU 2173680	C2	20010920	RU 1995-106624	19930824
AT 218541	E	20020615	AT 1997-113434	19930824
PT 810209	T	20020930	PT 1997-113434	19930824
ES 2177868	T3	20021216	ES 1997-113434	19930824
US 6060476	A	20000509	US 1994-204827	19940302
US 5968942	A	19991019	US 1994-294468	19940823
NO 9500533	A	19950213	NO 1995-533	19950213
FI 9500650	A	19950214	FI 1995-650	19950214
FI 112471	B1	20031215		
US 6455581	B1	20020924	US 1995-451090	19950525
US 6046190	A	20000404	US 1996-586866	19960124
NO 9803099	A	19950213	NO 1998-3099	19980703
NO 307047	B1	20000131		
US 6248775	B1	20010619	US 1999-288080	19990408
US 6500832	B1	20021231	US 2000-525161	20000314
US 2002052399	A1	20020502	US 2001-798255	20010305
US 6417387	B2	20020709		
FI 2001002317	A	20011127	FI 2001-2317	20011127
US 2003191319	A1	20031009	US 2002-157019	20020530
US 6646010	B2	20031111		
US 2004044047	A1	20040304	US 2002-199481	20020722
US 6846954	B2	20050125		
US 6924286	B1	20050802	US 2003-633376	20030804
US 2004229922	A1	20041118	US 2004-812343	20040330

PRIORITY APPLN. INFO.:	US 1992-934984	A2 19920825
	EP 1993-923714	A3 19930824
	US 1993-110911	A2 19930824
	WO 1993-US7814	W 19930824
	US 1994-204827	A2 19940302
	US 1994-204872	B2 19940302
	US 1994-294468	A1 19940823
	WO 1994-US9139	W 19940823
	US 1995-451090	A3 19950525
	US 1999-288080	A1 19990408
	US 2001-798255	A1 20010305
	US 2002-157019	A1 20020530
	US 2002-199481	A3 20020722

OTHER SOURCE(S): MARPAT 121:301324
GI



I



II



III

AB Title compds. [I and II; R = H, alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, heterocyclylcarbonyl, heteroaryloxyalkyl, hydroxyalkyl, aryl, alkyl, alkenyl, alkynyl, substituted aminocarbonyl, etc.; R' = H, R3, R''SO2; RR'N = heterocyclyl, heteroaryl; R1 = H, CH2SO2NH2, CH2CO2Me, CO2Me, CONH2, CMe2SH, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, amino acid side chains, etc.; R1', R1'' = H, R1; 1 of R1', R1'' together with R1 form a cycloalkyl radical; R2 = (substituted) alkyl, aryl, cycloalkyl, cycloalkylalkyl, aralkyl; R3 = H, alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, aryl, aralkyl, heteroaralkyl, (substituted) aminoalkyl, etc.; R4 = R3, except H; R6 = H, alkyl; x = 0-2; t = 0, 1; Y = O, S, imino], were prepared Thus, title compound (III, solution phase preparation given) inhibited HIV protease with IC50 = 16 nM.

IT 159005-89-7P 159005-90-0P 159005-91-1P 159005-92-2P 159005-95-5P 159006-21-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological

study); PREP (Preparation)
(prepn. of, as HIV protease inhibitor)

RN 159005-89-7 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(methylsulfonyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159005-90-0 CAPLUS
CN 2-Thia-3,7,10-triazaundecan-11-oic acid, 9-(2-amino-2-oxoethyl)-5-hydroxy-3-(3-methylbutyl)-8-oxo-6-(phenylmethyl)-, phenylmethyl ester, 2,2-dioxide, (5R,6S,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159005-91-1 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.



IT 159006-49-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as HIV protease inhibitor intermediate)

RN 159006-49-2 CAPLUS
CN Butanediamide, 2-amino-N1-[2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-N4-methyl-, monohydrochloride, [1S-[1R*(R*),2S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 159005-90-0P 159005-92-2P 159006-05-0P
159006-06-1P 159006-22-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for HIV protease inhibitor)

RN 159005-90-0 CAPLUS
CN 2-Thia-3,7,10-triazaundecan-11-oic acid, 9-(2-amino-2-oxoethyl)-5-hydroxy-3-(3-methylbutyl)-8-oxo-6-(phenylmethyl)-, phenylmethyl ester, 2,2-dioxide, (5R,6S,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159005-92-2 CAPLUS
CN Carbamic acid, [(1S)-3-amino-1-[[[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-3-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159005-95-5 CAPLUS
CN Butanediamide, N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-N4-methyl-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159006-21-0 CAPLUS
CN Carbamic acid, [(1S)-3-amino-1-[[[(1S,2R)-2-hydroxy-1-(phenylmethyl)-3-[(phenylsulfonyl)propylamino]propyl]amino]carbonyl]-3-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 159005-92-2 CAPLUS
CN Carbamic acid, [(1S)-3-amino-1-[[[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-3-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159006-05-0 CAPLUS
CN Butanediamide, 2-amino-N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(methylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159006-06-1 CAPLUS

L7 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Butanediamide, 2-amino-N1-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159006-22-1 CAPLUS
CN Carbamic acid, [(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-3-(methylamino)-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:579258 CAPLUS
DOCUMENT NUMBER: 121:179258
TITLE: N-(alkanoylamino-2-hydroxypropyl)sulfonamides useful as HIV protease inhibitors
INVENTOR(S): Vazquez, Michael L.; Mueller, Richard A.; Talley, John J.; Getman, Daniel; Decrescenzo, Gary A.; Freskos, John N.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA; Monsanto Co.
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9404491	A1	19940303	WO 1993-US7815	19930825
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 656886	A1	19950614	EP 1993-920213	19930824
EP 656886	B1	19970625		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 08500824	T2	19960130	JP 1993-506531	19930824
AT 154800	E	19970715	AT 1993-920213	19930824
ES 2103488	T3	19970916	ES 1993-920213	19930824
AU 674702	B2	19970109	AU 1993-50819	19930825
AU 9350819	A1	19940315		
RU 2130016	C1	19990510	RU 1995-106823	19930825
NO 9500670	A	19950222	NO 1995-670	19950222
FI 9500841	A	19950223	FI 1995-841	19950223
PRIORITY APPLN. INFO.:			US 1992-935490 A2	19920825
			WO 1993-US7815 W	19930825

OTHER SOURCE(S): MARPAT 121:179258
GI



I

AB The title compds. R33(R34)X1C(:Y1)(CH2)tC(R31)(R32)C(R30)(R1)C(:Y)N(R6)C(R2)HC(OH)HCH2N(R3)S(O)xR4 [R1 = H, CH2SO2NH2, CO2Me, CONHMe, CONMe2, etc.; R2 = alkyl, aryl, cycloalkyl, (un)substituted cycloalkylalkyl and arylalkyl; R3 = H, alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, etc.; R4 = alkyl, haloalkyl alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl etc.; R6 = H, alkyl; R30-R32 = R1; R1R30R31 = cycloalkyl; R1R30R32C = cycloalkyl; R33, R34 = H, R3; R33R34X1

L7 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
= cycloalkyl, aryl, heterocyclyl, etc.; X1 = O, N, CR17; R17 = H, alkyl; Y, Y1 = O, S, NR15; R15 = H, R3; t = 0, 1; x = 0-2], useful as HIV protease inhibitors for the treatment of AIDS, are prepd. Thus, sulfonamide I was prepd. and demonstrated IC50 against HIV protease of 1 nmol.
IT 157446-05-4 157446-06-5 157446-07-6
157446-08-7 157446-09-8 157474-44-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(HIV protease inhibitor)
RN 157446-05-4 CAPLUS
CN Butanediamide, N4-[(1S,2R)-2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](3-methylbutyl)amino]-1-(phenylmethyl)propyl]-2,2,3-trimethyl-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157446-06-5 CAPLUS
CN Butanoic acid, 4-[[2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](3-methylbutyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, phenylmethyl ester, [1S-[1R*(S*),2S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157446-07-6 CAPLUS
CN Butanediamide, N4-[(1S,2R)-3-[[(4-fluorophenyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2,2,3-trimethyl-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 157446-08-7 CAPLUS
CN Butanoic acid, 4-[[3-[[(4-fluorophenyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, phenylmethyl ester, [1S-[1R*(S*),2S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157446-09-8 CAPLUS
CN Butanoic acid, 4-[[3-[[(4-fluorophenyl)sulfonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, [1S-[1R*(S*),2S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157474-44-7 CAPLUS
CN Butanoic acid, 4-[[2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](3-methylbutyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, [1S-[1R*(S*),2S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **157445-96-0P 157445-97-1P 157445-98-2P**
157445-99-3P 157446-00-9P 157446-02-1P
157446-03-2P 157446-04-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as HIV protease inhibitor)

RN 157445-96-0 CAPLUS
CN Butanediamide, N4-[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]-2,2,3-trimethyl-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157445-97-1 CAPLUS
CN Butanoic acid, 4-[[2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, phenylmethyl ester, [1S-[1R*(S*),2S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157445-98-2 CAPLUS
CN Butanoic acid, 4-[[(1S,2R)-2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157445-99-3 CAPLUS
CN Butanoic acid, 4-[[2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, phenylmethyl ester, [1S-[1R*(S*),2S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157446-00-9 CAPLUS

CN Butanoic acid, 4-[[2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, [1S-[1R*(S*),2S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157446-02-1 CAPLUS
CN Butanoic acid, 4-[[2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, phenylmethyl ester, [1S-[1R*(S*),2S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157446-03-2 CAPLUS
CN Butanoic acid, 4-[[2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, [1S-[1R*(S*),2S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157446-04-3 CAPLUS
CN Butanediamide, N4-[(1S,2R)-2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-2,2,3-trimethyl-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
=> fil beilstein
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    95.21     418.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -13.87     -13.87

FILE 'BEILSTEIN' ENTERED AT 18:42:45 ON 11 AUG 2005
COPYRIGHT (c) 2005 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE RELOADED ON OCTOBER 20, 2002
FILE LAST UPDATED ON JUNE 29, 2005

FILE COVERS 1771 TO 2005.
*** FILE CONTAINS  9,271,550 SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in
   separate documents and can not be searched together in one query.
   Reaction data for BEILSTEIN compounds may be displayed
   immediately with the display codes PRE (preparations) and REA
   (reactions).  A substance answer set retrieved after the search
   for a chemical name, a compounds with available reaction
   information by combining with PRE/FA, REA/FA or more generally
   with RX/FA. The BEILSTEIN Registry Number (BRN) is the link
   between a BEILSTEIN compound and belonging reactions. For mo
   detailed reaction searches BRNs can be searched as reaction
   partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<
```

```
L8             1 SEA SSS SAM L4

=> s L4 full
FULL SEARCH INITIATED 18:42:59 FILE 'BEILSTEIN'
FULL SCREEN SEARCH COMPLETED -     164 TO ITERATE

100.0% PROCESSED      164 ITERATIONS                                  8 ANSWERS
SEARCH TIME: 00.00.07

L9             8 SEA SSS FUL L4

=> d L9 1-8
```

L9 ANSWER 1 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN

Beilstein Records (BRN):	8520503
Chemical Name (CN):	SC-98A
Autonom Name (AUN):	N-<3-<benzenesulfonyl-(3-methyl-butyl)-amino>-1-benzyl-2-hydroxy-propyl>-2,2,3-trimethyl-succinamic acid
Molec. Formula (MF):	C28 H40 N2 O6 S
Molecular Weight (MW):	532.69
Lawson Number (LN):	14921, 13803, 2854, 1556
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	isocyclic
Constitution ID (CONSID):	7222898
Tautomer ID (TAUTID):	8021132
Entry Date (DED):	2000/07/18
Update Date (DUPD):	2000/07/18



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	4
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
DED	Entry Date	1
DUPD	Update Date	1
PHARM	Pharmacological Data	2

Pharmacological Data:

L9 ANSWER 1 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN (Continued)

PHARM

Effect (.E):	protein binding
Species or Test-System (.SP):	rat plasma
Concentration (.C):	0.3 - 30 mg/l
Method, Remarks (.MR):	<14C>labeled title comp. (spec. act.: 117 .my.Ci/mg); 22 deg C; charcoal protein binding assay: contact time 14 min; ultrafiltration protein binding assay
Results (.RE):	protein binding (percent unbound) (ultrafiltration/charcoal adsorption)/at dose (.my.g/ml): 91.6/86.8/0.3, 91.0/86.0/1.0, and 89.6/85.5/3.0

Reference(s):

1. Yuan, Jinhua; Yang, Dai Chang; Birkmeier, Jill; Stolzenbach, James, J.Parmacokinet.Biopharm., CODEN: JPBPBJ, 23(1), <1995>, 41 - 56; BABS-6228589

PHARM

Effect (.E):	protein binding
Species or Test-System (.SP):	human albumin
Concentration (.C):	0.3 mg/l
Method, Remarks (.MR):	<14C>labeled title comp. (spec. act.: 117 .my.Ci/mg); 22 deg C; charcoal protein binding assay: contact time 14 min
Results (.RE):	protein binding: ca. 78 percent

Reference(s):

1. Yuan, Jinhua; Yang, Dai Chang; Birkmeier, Jill; Stolzenbach, James, J.Parmacokinet.Biopharm., CODEN: JPBPBJ, 23(1), <1995>, 41 - 56; BABS-6228589

L9 ANSWER 2 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7676982
Chemical Name (CN):	4-(4-<2-(2-amino-3-carbamoyl-propionylamino)-4-<benzenesulfonyl-(3-methyl-butyl)-amino>-3-hydroxy-butyl>-phenoxy)-butyric acid
Autonom Name (AUN):	4-(4-<2-(2-amino-3-carbamoyl-propionylamino)-4-<benzenesulfonyl-(3-methyl-butyl)-amino>-3-hydroxy-butyl>-phenoxy)-butyric acid
Molec. Formula (MF):	C29 H42 N4 O8 S
Molecular Weight (MW):	606.73
Lawson Number (LN):	15202, 13803, 3487, 2854, 1789
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	isocyclic
Constitution ID (CONSID):	6553042
Tautomer ID (TAUTID):	7265790
Beilstein Citation (BSO):	6-13
Entry Date (DED):	1997/07/31
Update Date (DUPD):	1998/03/04



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	5
FS	File Segment	1

L9 ANSWER 2 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN (Continued)

CTYPE	Compound Type 1
CONSID	Constitution ID 1
TAUTID	Tautomer ID 1
BSO	Beilstein Citation 1
DED	Entry Date 1
DUPD	Update Date 1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	2
RXREA	Substance is Reaction Reactant	1
RXPRO	Substance is Reaction Product	1

Reaction:
RX

Reaction ID (.ID):	4616107
Reactant BRN (.RBRN):	7446269, 7668064, 1977963
Reactant (.RCT):	1-bromo-(S)-3-<(tert-butoxycarbonyl)amino>-4-<4'-<(3'-carbethoxypropyl)oxy>phenyl>-2-butanone, N-(3-methyl-butyl)-benzenesulfonamide; hydrochloride, BOC-L-asparagine
Product BRN (.PBRN):	7676982
Product (.PRO):	4-(4-<2-(2-amino-3-carbamoyl-propionylamino)-4-<benzenesulfonyl-(3-methyl-butyl)-amino>-3-hydroxy-butyl>-phenoxy)-butyric acid
No. of React. Details (.NVAR):	1

Reaction Details:
RX

Reaction RID (.RID):	4616107.1
Reaction Classification (.CL):	Preparation
Reagent (.RGT):	1.) DIPEA, 2.) NaBH4, 3.) HCl, 4.) HBTU, DIPEA, 5.) NaOH

Reference(s):
1. Abbenante, G.; Bergman, D. A.; Brinkworth, R. I.; March, D. R.; Reid, R. C.; et al., Bioorg.Med.Chem.Lett., CODEN: BMCLE8, 6(21), <1996>, 2531-2536; BABS-6047699

Reaction:
RX

Reaction ID (.ID):	4653938
Reactant BRN (.RBRN):	7676982
Reactant (.RCT):	4-(4-<2-(2-amino-3-carbamoyl-propionylamino)-4-<benzenesulfonyl-(3-methyl-butyl)-amino>-3-hydroxy-butyl>-phenoxy)-butyric acid
Product BRN (.PBRN):	7676583
Product (.PRO):	2-(11-<2-<benzenesulfonyl-(3-methyl-butyl)-amino>-1-hydroxy-ethyl>-6,9-dioxo-2-oxa-7,10-diaza-bicyclo<11.2.2>heptadeca-1(16),13(17),14-trien-8-yl)-acetamide
No. of React. Details (.NVAR):	1

Reaction Details:
RX

Reaction RID (.RID):	4653938.1

L9 ANSWER 2 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN (Continued)

Reaction Classification (.CL):	Preparation
Reagent (.RGT):	BOP, DIPEA

Reference(s):
1. Abbenante, G.; Bergman, D. A.; Brinkworth, R. I.; March, D. R.; Reid, R. C.; et al., Bioorg.Med.Chem.Lett., CODEN: BMCLE8, 6(21), <1996>, 2531-2536; BABS-6047699

L9 ANSWER 3 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7241722
Chemical Name (CN):	N1-<3-<benzenesulfonyl-(3-methyl-butyl)-amino>-1-benzyl-2-hydroxy-propyl>-2-<(quinoline-2-carbonyl)-amino>-succinamide
Autonom Name (AUN):	N1-<3-<benzenesulfonyl-(3-methyl-butyl)-amino>-1-benzyl-2-hydroxy-propyl>-2-<(quinoline-2-carbonyl)-amino>-succinamide
Molec. Formula (MF):	C35 H41 N5 O6 S
Molecular Weight (MW):	659.80
Lawson Number (LN):	26398, 14921, 13803, 3487, 2854
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6237125
Tautomer ID (TAUTID):	6902601
Beilstein Citation (BSO):	6-22
Entry Date (DED):	1995/10/31
Update Date (DUPD):	1996/08/09



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	5
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
DED	Entry Date	1
DUPD	Update Date	1
PHARM	Pharmacological Data	1

This substance also occurs in Reaction Documents:

L9 ANSWER 3 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN (Continued)

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

Pharmacological Data:
PHARM

Note(s) (.COM):	inhibition of recombinant HIV-1 protease (IC50 1.5 nM); antiviral activity against the HIVIIIB strain of HIV-1 in a CEM cells (EC50 5 nM)

Reference(s):
1. Vazquez, Michael L.; Bryant, Martin L.; Clare, Michael; DeCrescenzo, Gary A.; Doherty, Elizabeth M.; et al., J.Med.Chem., CODEN: JMCMAR, 38(4), <1995>, 581-584; BABS-5961570

Reaction:
RX

Reaction ID (.ID):	4177267
Reactant BRN (.RBRN):	7236620, 5875502
Reactant (.RCT):	2-amino-N1-<3-<benzenesulfonyl-(3-methyl-butyl)-amino>-1-benzyl-2-hydroxy-propyl>-succinamide, quinoline-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester
Product BRN (.PBRN):	7241722
Product (.PRO):	N1-<3-<benzenesulfonyl-(3-methyl-butyl)-amino>-1-benzyl-2-hydroxy-propyl>-2-<(quinoline-2-carbonyl)-amino>-succinamide
No. of React. Details (.NVAR):	1

Reaction Details:
RX

Reaction RID (.RID):	4177267.1
Reaction Classification (.CL):	Preparation

Reference(s):
1. Vazquez, Michael L.; Bryant, Martin L.; Clare, Michael; DeCrescenzo, Gary A.; Doherty, Elizabeth M.; et al., J.Med.Chem., CODEN: JMCMAR, 38(4), <1995>, 581-584; BABS-5961570

L9 ANSWER 4 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7241365
Chemical Name (CN):	(1-<3-<benzenesulfonyl-(3-methyl-butyl)-amino>-1-benzyl-2-hydroxy-propylcarbamoyl>-2-carbamoyl-ethyl)-carbamic acid benzyl ester
Autonom Name (AUN):	(1-<3-<benzenesulfonyl-(3-methyl-butyl)-amino>-1-benzyl-2-hydroxy-propylcarbamoyl>-2-carbamoyl-ethyl)-carbamic acid benzyl ester
Molec. Formula (MF):	C33 H42 N4 O7 S
Molecular Weight (MW):	638.78
Lawson Number (LN):	14921, 13803, 5228, 3487, 2854, 1762
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	isocyclic
Constitution ID (CONSID):	6235878
Tautomer ID (TAUTID):	6895358
Beilstein Citation (BSO):	6-13
Entry Date (DED):	1995/10/31
Update Date (DUPD):	1996/08/09



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	6
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
DED	Entry Date	1

L9 ANSWER 4 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN (Continued)

DUPD	Update Date	1
PHARM	Pharmacological Data	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	2
RXREA	Substance is Reaction Reactant	1
RXPRO	Substance is Reaction Product	1

Pharmacological Data:
PHARM

Note(s) (.COM):	inhibition of recombinant HIV-1 protease (IC50 2.2 nM)

Reference(s):
1. Vazquez, Michael L.; Bryant, Martin L.; Clare, Michael; DeCrescenzo, Gary A.; Doherty, Elizabeth M.; et al., J.Med.Chem., CODEN: JMCMAR, 38(4), <1995>, 581-584; BABS-5961570

Reaction:
RX

Reaction ID (.ID):	4164071
Reactant BRN (.RBRN):	7225655, 3085452
Reactant (.RCT):	N-(3-amino-2-hydroxy-4-phenyl-butyl)-N-(3-methyl-butyl)-benzenesulfonamide, N2-benzyloxycarbonyl-L-asparagine
Product BRN (.PBRN):	7241365
Product (.PRO):	(1-<3-<benzenesulfonyl-(3-methyl-butyl)-amino>-1-benzyl-2-hydroxy-propylcarbamoyl>-2-carbamoyl-ethyl)-carbamic acid benzyl ester
No. of React. Details (.NVAR):	1

Reaction Details:
RX

Reaction RID (.RID):	4164071.1
Reaction Classification (.CL):	Preparation
Reagent (.RGT):	HOBt, EDC
Solvent (.SOL):	dimethylformamide

Reference(s):
1. Vazquez, Michael L.; Bryant, Martin L.; Clare, Michael; DeCrescenzo, Gary A.; Doherty, Elizabeth M.; et al., J.Med.Chem., CODEN: JMCMAR, 38(4), <1995>, 581-584; BABS-5961570

Reaction:
RX

Reaction ID (.ID):	4197780
Reactant BRN (.RBRN):	7241365
Reactant (.RCT):	(1-<3-<benzenesulfonyl-(3-methyl-butyl)-amino>-1-benzyl-2-hydroxy-propylcarbamoyl>-2-carbamoyl-ethyl)-carbamic acid benzyl ester
Product BRN (.PBRN):	7236620
Product (.PRO):	2-amino-N1-<3-<benzenesulfonyl-(3-methyl-butyl)-amino>-1-benzyl-2-hydroxy-propyl>-succinamide
No. of React. Details (.NVAR):	1

Reaction Details:

L9 ANSWER 4 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN (Continued)
RX

Reaction RID (.RID):	4197780.1
Reaction Classification (.CL):	Preparation
Reagent (.RGT):	H2
Catalyst (.CAT):	10percent Pd/C
Solvent (.SOL):	methanol

Reference(s):
1. Vazquez, Michael L.; Bryant, Martin L.; Clare, Michael; DeCrescenzo, Gary A.; Doherty, Elizabeth M.; et al., J.Med.Chem., CODEN: JMCMAR, 38(4), <1995>, 581-584; BABS-5961570

L9 ANSWER 5 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7239075
Chemical Name (CN):	N1-<1-benzyl-2-hydroxy-3-<methanesulfonyl-(3-methyl-butyl)-amino>-propyl>-2-<(quinoline-2-carbonyl)-amino>-succinamide
Autonom Name (AUN):	N1-<1-benzyl-2-hydroxy-3-<methanesulfonyl-(3-methyl-butyl)-amino>-propyl>-2-<(quinoline-2-carbonyl)-amino>-succinamide
Molec. Formula (MF):	C30 H39 N5 O6 S
Molecular Weight (MW):	597.73
Lawson Number (LN):	26398, 14921, 3487, 2854, 2705
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6235067
Tautomer ID (TAUTID):	6903688
Beilstein Citation (BSO):	6-22
Entry Date (DED):	1995/10/31
Update Date (DUPD):	1996/08/09



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	5
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
DED	Entry Date	1
DUPD	Update Date	1
PHARM	Pharmacological Data	1

L9 ANSWER 5 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN (Continued)

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

Pharmacological Data:

PHARM

Note(s) (.COM):	inhibition of recombinant HIV-1 protease (IC50 27 nM); antiviral activity against the HIVIIIB strain of HIV-1 in a CEM cells (EC50 53 nM)

Reference(s):

1. Vazquez, Michael L.; Bryant, Martin L.; Clare, Michael; DeCrescenzo, Gary A.; Doherty, Elizabeth M.; et al., J.Med.Chem., CODEN: JMCMAR, 38(4), <1995>, 581-584; BABS-5961570

Reaction:

RX

Reaction ID (.ID):	4177266
Reactant BRN (.RBRN):	7230903, 5875502
Reactant (.RCT):	2-amino-N1-<1-benzyl-2-hydroxy-3-<methanesulfonyl-(3-methyl-butyl)-amino>-propyl>-succinamide, quinoline-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester
Product BRN (.PBRN):	7239075
Product (.PRO):	N1-<1-benzyl-2-hydroxy-3-<methanesulfonyl-(3-methyl-butyl)-amino>-propyl>-2-<(quinoline-2-carbonyl)-amino>-succinamide
No. of React. Details (.NVAR):	1

Reaction Details:

RX

Reaction RID (.RID):	4177266.1
Reaction Classification (.CL):	Preparation

Reference(s):

1. Vazquez, Michael L.; Bryant, Martin L.; Clare, Michael; DeCrescenzo, Gary A.; Doherty, Elizabeth M.; et al., J.Med.Chem., CODEN: JMCMAR, 38(4), <1995>, 581-584; BABS-5961570

L9 ANSWER 6 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7238525
Chemical Name (CN):	(1-<1-benzyl-2-hydroxy-3-<methanesulfonyl-(3-methyl-butyl)-amino>-propylcarbamoyl>-2-carbamoyl-ethyl)-carbamic acid benzyl ester
Autonom Name (AUN):	(1-<1-benzyl-2-hydroxy-3-<methanesulfonyl-(3-methyl-butyl)-amino>-propylcarbamoyl>-2-carbamoyl-ethyl)-carbamic acid benzyl ester
Molec. Formula (MF):	C28 H40 N4 O7 S
Molecular Weight (MW):	576.71
Lawson Number (LN):	14921, 5228, 3487, 2854, 2705, 1762
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	isocyclic
Constitution ID (CONSID):	6232600
Tautomer ID (TAUTID):	6898701
Beilstein Citation (BSO):	6-13
Entry Date (DED):	1995/10/31
Update Date (DUPD):	1996/08/09



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	6
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1

L9 ANSWER 6 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN (Continued)

DED	Entry Date	1
DUPD	Update Date	1
PHARM	Pharmacological Data	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	2
RXREA	Substance is Reaction Reactant	1
RXPRO	Substance is Reaction Product	1

Pharmacological Data:

PHARM

Note(s) (.COM):	inhibition of recombinant HIV-1 protease (IC50 100 nM)

Reference(s):

1. Vazquez, Michael L.; Bryant, Martin L.; Clare, Michael; DeCrescenzo, Gary A.; Doherty, Elizabeth M.; et al., J.Med.Chem., CODEN: JMCMAR, 38(4), <1995>, 581-584; BABS-5961570

Reaction:

RX

Reaction ID (.ID):	4164070
Reactant BRN (.RBRN):	7213958, 3085452
Reactant (.RCT):	N-(3-amino-2-hydroxy-4-phenyl-butyl)-N-(3-methyl-butyl)-methanesulfonamide, N2-benzyloxycarbonyl-L-asparagine
Product BRN (.PBRN):	7238525
Product (.PRO):	(1-<1-benzyl-2-hydroxy-3-<methanesulfonyl-(3-methyl-butyl)-amino>-propylcarbamoyl>-2-carbamoyl-ethyl)-carbamic acid benzyl ester
No. of React. Details (.NVAR):	1

Reaction Details:

RX

Reaction RID (.RID):	4164070.1
Reaction Classification (.CL):	Preparation
Reagent (.RGT):	HOBt, EDC
Solvent (.SOL):	dimethylformamide

Reference(s):

1. Vazquez, Michael L.; Bryant, Martin L.; Clare, Michael; DeCrescenzo, Gary A.; Doherty, Elizabeth M.; et al., J.Med.Chem., CODEN: JMCMAR, 38(4), <1995>, 581-584; BABS-5961570

Reaction:

RX

Reaction ID (.ID):	4197018
Reactant BRN (.RBRN):	7238525
Reactant (.RCT):	(1-<1-benzyl-2-hydroxy-3-<methanesulfonyl-(3-methyl-butyl)-amino>-propylcarbamoyl>-2-carbamoyl-ethyl)-carbamic acid benzyl ester
Product BRN (.PBRN):	7230903
Product (.PRO):	2-amino-N1-<1-benzyl-2-hydroxy-3-<methanesulfonyl-(3-methyl-butyl)-amino>-propyl>-succinamide
No. of React. Details (.NVAR):	1

L9 ANSWER 6 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN (Continued)

Reaction Details:

RX

Reaction RID (.RID):	4197018.1
Reaction Classification (.CL):	Preparation
Reagent (.RGT):	H2
Catalyst (.CAT):	10percent Pd/C
Solvent (.SOL):	methanol
Reference(s):	

1. Vazquez, Michael L.; Bryant, Martin L.; Clare, Michael; DeCrescenzo, Gary A.; Doherty, Elizabeth M.; et al., J.Med.Chem., CODEN: JMCMAR, 38(4), <1995>, 581-584; BABS-5961570

L9 ANSWER 7 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7236620
Chemical Name (CN):	2-amino-N1-<3-<benzenesulfonyl-(3-methyl-butyl)-amino>-1-benzyl-2-hydroxy-propyl>-succinamide
Autonom Name (AUN):	2-amino-N1-<3-<benzenesulfonyl-(3-methyl-butyl)-amino>-1-benzyl-2-hydroxy-propyl>-succinamide
Molec. Formula (MF):	C25 H36 N4 O5 S
Molecular Weight (MW):	504.64
Lawson Number (LN):	14921, 13803, 3487, 2854
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	isocyclic
Constitution ID (CONSID):	6228077
Tautomer ID (TAUTID):	6887578
Beilstein Citation (BSO):	6-13
Entry Date (DED):	1995/10/31
Update Date (DUPD):	1996/08/09



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	4
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1

L9 ANSWER 7 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN (Continued)

DED	Entry Date	1
DUPD	Update Date	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	2
RXREA	Substance is Reaction Reactant	1
RXPRO	Substance is Reaction Product	1

Reaction:

RX

Reaction ID (.ID):	4197780
Reactant BRN (.RBRN):	7241365
Reactant (.RCT):	(1-<3-<benzenesulfonyl-(3-methyl-butyl)-amino>-1-benzyl-2-hydroxy-propylcarbamoyl>-2-carbamoyl-ethyl)-carbamic acid benzyl ester
Product BRN (.PBRN):	7236620
Product (.PRO):	2-amino-N1-<3-<benzenesulfonyl-(3-methyl-butyl)-amino>-1-benzyl-2-hydroxy-propyl>-succinamide
No. of React. Details (.NVAR):	1

Reaction Details:

RX

Reaction RID (.RID):	4197780.1
Reaction Classification (.CL):	Preparation
Reagent (.RGT):	H2
Catalyst (.CAT):	10percent Pd/C
Solvent (.SOL):	methanol
Reference(s):	

1. Vazquez, Michael L.; Bryant, Martin L.; Clare, Michael; DeCrescenzo, Gary A.; Doherty, Elizabeth M.; et al., J.Med.Chem., CODEN: JMCMAR, 38(4), <1995>, 581-584; BABS-5961570

Reaction:

RX

Reaction ID (.ID):	4177267
Reactant BRN (.RBRN):	7236620, 5875502
Reactant (.RCT):	2-amino-N1-<3-<benzenesulfonyl-(3-methyl-butyl)-amino>-1-benzyl-2-hydroxy-propyl>-succinamide, quinoline-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester
Product BRN (.PBRN):	7241722
Product (.PRO):	N1-<3-<benzenesulfonyl-(3-methyl-butyl)-amino>-1-benzyl-2-hydroxy-propyl>-2-<(quinoline-2-carbonyl)-amino>-succinamide
No. of React. Details (.NVAR):	1

Reaction Details:

RX

Reaction RID (.RID):	4177267.1
Reaction Classification (.CL):	Preparation
Reference(s):	

1. Vazquez, Michael L.; Bryant, Martin L.; Clare, Michael; DeCrescenzo, Gary A.; Doherty, Elizabeth M.; et al., J.Med.Chem., CODEN: JMCMAR, 38(4), <1995>, 581-584; BABS-5961570

L9 ANSWER 7 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN (Continued)

L9 ANSWER 8 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7230903
Chemical Name (CN):	2-amino-N1-<1-benzyl-2-hydroxy-3-<methanesulfonyl-(3-methyl-butyl)-amino>-propyl>-succinamide
Autonom Name (AUN):	2-amino-N1-<1-benzyl-2-hydroxy-3-<methanesulfonyl-(3-methyl-butyl)-amino>-propyl>-succinamide
Molec. Formula (MF):	C20 H34 N4 O5 S
Molecular Weight (MW):	442.57
Lawson Number (LN):	14921, 3487, 2854, 2705
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	isocyclic
Constitution ID (CONSID):	6224271
Tautomer ID (TAUTID):	6892172
Beilstein Citation (BSO):	6-13
Entry Date (DED):	1995/10/31
Update Date (DUPD):	1996/08/09



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	4
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1

L9 ANSWER 8 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN (Continued)

DED	Entry Date	1
DUPD	Update Date	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	2
RXREA	Substance is Reaction Reactant	1
RXPRO	Substance is Reaction Product	1

Reaction:
RX

Reaction ID (.ID):	4197018
Reactant BRN (.RBRN):	7238525
Reactant (.RCT):	(1-<1-benzyl-2-hydroxy-3-<methanesulfonyl-(3-methyl-butyl)-amino>-propylcarbamoyl>-2-carbamoyl-ethyl)-carbamic acid benzyl ester
Product BRN (.PBRN):	7230903
Product (.PRO):	2-amino-N1-<1-benzyl-2-hydroxy-3-<methanesulfonyl-(3-methyl-butyl)-amino>-propyl>-succinamide
No. of React. Details (.NVAR):	1

Reaction Details:
RX

Reaction RID (.RID):	4197018.1
Reaction Classification (.CL):	Preparation
Reagent (.RGT):	H2
Catalyst (.CAT):	10percent Pd/C
Solvent (.SOL):	methanol

Reference(s):
1. Vazquez, Michael L.; Bryant, Martin L.; Clare, Michael; DeCrescenzo, Gary A.; Doherty, Elizabeth M.; et al., J.Med.Chem., CODEN: JMCMAR, 38(4), <1995>, 581-584; BABS-5961570

Reaction:
RX

Reaction ID (.ID):	4177266
Reactant BRN (.RBRN):	7230903, 5875502
Reactant (.RCT):	2-amino-N1-<1-benzyl-2-hydroxy-3-<methanesulfonyl-(3-methyl-butyl)-amino>-propyl>-succinamide, quinoline-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester
Product BRN (.PBRN):	7239075
Product (.PRO):	N1-<1-benzyl-2-hydroxy-3-<methanesulfonyl-(3-methyl-butyl)-amino>-propyl>-2-<(quinoline-2-carbonyl)-amino>-succinamide
No. of React. Details (.NVAR):	1

Reaction Details:
RX

Reaction RID (.RID):	4177266.1
Reaction Classification (.CL):	Preparation

Reference(s):
1. Vazquez, Michael L.; Bryant, Martin L.; Clare, Michael; DeCrescenzo, Gary A.; Doherty, Elizabeth M.; et al., J.Med.Chem., CODEN: JMCMAR, 38(4), <1995>, 581-584; BABS-5961570

L9 ANSWER 8 OF 8 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN (Continued)